Trial Outcomes & Findings for A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) (NCT NCT03157128)
NCT ID: NCT03157128
Last Updated: 2026-04-16
Results Overview
The MTD is defined as the highest dose level at which none of the first 3 treated patients, or not more than 1 of the first 6 treated patients, experiences a DLT. A DLT is any adverse events that starts on or after first administration of study drug, as defined by National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0. * Any Grade(G) ≥3 nonhematologic toxicity, excluding * G3 AST, ALT, and/or total bilirubin elevation for \<7 days. * G3 neutropenia \<7 days * G3 thrombocytopenia without clinically significant bleeding * G3 or G4 lymphopenia. * First occurrence of G3 or G4 electrolyte abnormalities * G3 fatigue, weakness, nausea; other manageable constitutional symptom * G3 or G4 vomiting or diarrhea that lasts for \<48hours with antiemetic/antidiarrheal medication in case of G3 and \<24 hours in case of G4 * G4 manageable constitutional symptom.
Recruitment status
ACTIVE_NOT_RECRUITING
Study phase
PHASE1/PHASE2
Target enrollment
857 participants
Primary outcome timeframe
Cycle 1 (cycle length = 28 days)
Results posted on
2026-04-16
Participant Flow
This study includes two parts: * Phase 1 (dose escalation) and; * Phase 2 (dose expansion) In Phase 1, participants received selpercatinib, with dosing based on body surface area. The Phase 2 portion of the study was opened after confirmation of the RP2D of 160 mg BID.
In Phase 2, participants were assigned to one of six tumor-based groups: RET Fusion Solid Tumor, RET Fusion Solid Tumor Without Standard Therapy, RET Mutant MTC, RET Mutant MTC Without Standard Therapy, Advanced RET Altered Solid Tumor, RET Inhibitor-Discontinued Participants and received selpercatinib at the RP2D. The current results reported are for the primary completion date (i.e., up to 7 years 9 months). Additional results will be reported at the time of final results reporting.
Participant milestones
| Measure |
Phase 1: 20 mg Selpercatinib QD
Participants received Selpercatinib 20 milligrams (mg) administered orally once daily (QD), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 20 mg Selpercatinib BID
Participants received Selpercatinib 20 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 40 mg Selpercatinib BID
Participants received Selpercatinib 40 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 60 mg Selpercatinib BID
Participants received Selpercatinib 60 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 160 mg Selpercatinib QD
Participants received Selpercatinib 160 milligrams (mg) administered orally once daily (QD), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 80 mg Selpercatinib BID
Participants received Selpercatinib 80 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 120 mg Selpercatinib BID
Participants received Selpercatinib 120 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 160 mg Selpercatinib BID
Participants received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 200 mg Selpercatinib BID
Participants received Selpercatinib 200 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 240 mg Selpercatinib BID
Participants received Selpercatinib 240 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 2, Cohort 1: RET Fusion Solid Tumor
Participants with Rearranged during transfection (RET) Fusion solid tumor progressed on/intolerant to standard first line therapy received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 2, Cohort 2: RET Fusion Solid Tumor Without Standard Therapy
Participants with RET Fusion solid tumor without standard first line therapy received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 2, Cohort 3: RET Mutant MTC
Participants with RET mutant medullary thyroid cancer (MTC) progressed on/intolerant to standard first line therapy received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 2, Cohort 4: RET Mutant MTC Without Standard Therapy
Participants with RET mutant MTC without prior standard first line therapy or other kinase inhibitor(s) with anti-RET activity received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 2, Cohort 5: Advanced RET Altered Solid Tumor
Participants with RET altered solid tumor (cohorts 1-4, disease not measurable; MTC not eligible for Cohort 3 or 4; MTC syndrome spectrum cancer; circulating free tumor DNA \[cfDNA+\] for RET alteration not known to be present in tumor) received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 2, Cohort 6: RET Inhibitor-Discontinued Participants
Participants otherwise eligible for Cohorts 1-5 who discontinued other RET inhibitors received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Phase 1 (Dose Escalation)
COMPLETED
|
6
|
10
|
16
|
12
|
1
|
20
|
19
|
764
|
3
|
6
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Phase 1 (Dose Escalation)
STARTED
|
6
|
10
|
16
|
12
|
1
|
20
|
19
|
764
|
3
|
6
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Phase 1 (Dose Escalation)
NOT COMPLETED
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Phase 2 (Dose Expansion)
STARTED
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
307
|
74
|
143
|
116
|
201
|
16
|
|
Phase 2 (Dose Expansion)
COMPLETED
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Phase 2 (Dose Expansion)
NOT COMPLETED
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
307
|
74
|
143
|
116
|
201
|
16
|
Reasons for withdrawal
| Measure |
Phase 1: 20 mg Selpercatinib QD
Participants received Selpercatinib 20 milligrams (mg) administered orally once daily (QD), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 20 mg Selpercatinib BID
Participants received Selpercatinib 20 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 40 mg Selpercatinib BID
Participants received Selpercatinib 40 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 60 mg Selpercatinib BID
Participants received Selpercatinib 60 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 160 mg Selpercatinib QD
Participants received Selpercatinib 160 milligrams (mg) administered orally once daily (QD), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 80 mg Selpercatinib BID
Participants received Selpercatinib 80 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 120 mg Selpercatinib BID
Participants received Selpercatinib 120 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 160 mg Selpercatinib BID
Participants received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 200 mg Selpercatinib BID
Participants received Selpercatinib 200 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 240 mg Selpercatinib BID
Participants received Selpercatinib 240 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 2, Cohort 1: RET Fusion Solid Tumor
Participants with Rearranged during transfection (RET) Fusion solid tumor progressed on/intolerant to standard first line therapy received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 2, Cohort 2: RET Fusion Solid Tumor Without Standard Therapy
Participants with RET Fusion solid tumor without standard first line therapy received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 2, Cohort 3: RET Mutant MTC
Participants with RET mutant medullary thyroid cancer (MTC) progressed on/intolerant to standard first line therapy received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 2, Cohort 4: RET Mutant MTC Without Standard Therapy
Participants with RET mutant MTC without prior standard first line therapy or other kinase inhibitor(s) with anti-RET activity received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 2, Cohort 5: Advanced RET Altered Solid Tumor
Participants with RET altered solid tumor (cohorts 1-4, disease not measurable; MTC not eligible for Cohort 3 or 4; MTC syndrome spectrum cancer; circulating free tumor DNA \[cfDNA+\] for RET alteration not known to be present in tumor) received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 2, Cohort 6: RET Inhibitor-Discontinued Participants
Participants otherwise eligible for Cohorts 1-5 who discontinued other RET inhibitors received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Phase 2 (Dose Expansion)
Ongoing
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
61
|
21
|
43
|
67
|
58
|
6
|
|
Phase 2 (Dose Expansion)
Withdrawal by Subject
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
33
|
7
|
13
|
11
|
27
|
1
|
|
Phase 2 (Dose Expansion)
Lost to Follow-up
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
7
|
4
|
3
|
3
|
4
|
1
|
|
Phase 2 (Dose Expansion)
Death
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
147
|
27
|
67
|
18
|
83
|
8
|
|
Phase 2 (Dose Expansion)
Sponsor's decision
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
34
|
9
|
5
|
12
|
12
|
0
|
|
Phase 2 (Dose Expansion)
Moved to commercial supply of drug
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
17
|
2
|
5
|
0
|
3
|
0
|
|
Phase 2 (Dose Expansion)
Disease progression
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
0
|
1
|
1
|
0
|
|
Phase 2 (Dose Expansion)
Physician Decision
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
5
|
0
|
1
|
0
|
1
|
0
|
|
Phase 2 (Dose Expansion)
Discontinued due to Continued Access
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
2
|
1
|
2
|
11
|
0
|
|
Phase 2 (Dose Expansion)
Alternative treatment therapy/SOC drug
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
0
|
0
|
0
|
|
Phase 2 (Dose Expansion)
Enrolled for another trial
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
0
|
0
|
0
|
|
Phase 2 (Dose Expansion)
Participant's Non-compliant
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
|
Phase 2 (Dose Expansion)
Participant unable to travel to site
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
|
Phase 2 (Dose Expansion)
Study transfer to derive more clinical benefit
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
|
Phase 2 (Dose Expansion)
developed a secondary malignancy and is no longer qualified for this study
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
Baseline Characteristics
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
Baseline characteristics by cohort
| Measure |
Phase 1: 20 mg Selpercatinib QD
n=6 Participants
Participants received Selpercatinib 20 milligrams (mg) administered orally once daily (QD), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 20 mg Selpercatinib BID
n=10 Participants
Participants received Selpercatinib 20 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 40 mg Selpercatinib BID
n=16 Participants
Participants received Selpercatinib 40 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 60 mg Selpercatinib BID
n=12 Participants
Participants received Selpercatinib 60 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 160 mg Selpercatinib QD
n=1 Participants
Participants received Selpercatinib 160 milligrams (mg) administered orally once daily (QD), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 80 mg Selpercatinib BID
n=20 Participants
Participants received Selpercatinib 80 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 120 mg Selpercatinib BID
n=19 Participants
Participants received Selpercatinib 120 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 160 mg Selpercatinib BID
n=764 Participants
Participants received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 200 mg Selpercatinib BID
n=3 Participants
Participants received Selpercatinib 200 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 240 mg Selpercatinib BID
n=6 Participants
Participants received Selpercatinib 240 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Total
n=857 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sex: Female, Male
Male
|
2 Participants
n=193 Participants
|
5 Participants
n=193 Participants
|
9 Participants
n=386 Participants
|
7 Participants
n=13 Participants
|
1 Participants
n=43 Participants
|
13 Participants
n=1 Participants
|
9 Participants
n=8 Participants
|
386 Participants
n=21 Participants
|
2 Participants
n=113 Participants
|
2 Participants
n=7 Participants
|
436 Participants
n=3 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=193 Participants
|
1 Participants
n=193 Participants
|
0 Participants
n=386 Participants
|
0 Participants
n=13 Participants
|
0 Participants
n=43 Participants
|
0 Participants
n=1 Participants
|
1 Participants
n=8 Participants
|
38 Participants
n=21 Participants
|
0 Participants
n=113 Participants
|
0 Participants
n=7 Participants
|
40 Participants
n=3 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=193 Participants
|
0 Participants
n=193 Participants
|
0 Participants
n=386 Participants
|
0 Participants
n=13 Participants
|
0 Participants
n=43 Participants
|
2 Participants
n=1 Participants
|
1 Participants
n=8 Participants
|
36 Participants
n=21 Participants
|
0 Participants
n=113 Participants
|
0 Participants
n=7 Participants
|
39 Participants
n=3 Participants
|
|
Age, Categorical
<=18 years
|
0 Participants
n=193 Participants
|
0 Participants
n=193 Participants
|
0 Participants
n=386 Participants
|
0 Participants
n=13 Participants
|
0 Participants
n=43 Participants
|
1 Participants
n=1 Participants
|
0 Participants
n=8 Participants
|
2 Participants
n=21 Participants
|
0 Participants
n=113 Participants
|
0 Participants
n=7 Participants
|
3 Participants
n=3 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
5 Participants
n=193 Participants
|
6 Participants
n=193 Participants
|
11 Participants
n=386 Participants
|
9 Participants
n=13 Participants
|
0 Participants
n=43 Participants
|
11 Participants
n=1 Participants
|
13 Participants
n=8 Participants
|
495 Participants
n=21 Participants
|
2 Participants
n=113 Participants
|
4 Participants
n=7 Participants
|
556 Participants
n=3 Participants
|
|
Age, Categorical
>=65 years
|
1 Participants
n=193 Participants
|
4 Participants
n=193 Participants
|
5 Participants
n=386 Participants
|
3 Participants
n=13 Participants
|
1 Participants
n=43 Participants
|
8 Participants
n=1 Participants
|
6 Participants
n=8 Participants
|
267 Participants
n=21 Participants
|
1 Participants
n=113 Participants
|
2 Participants
n=7 Participants
|
298 Participants
n=3 Participants
|
|
Sex: Female, Male
Female
|
4 Participants
n=193 Participants
|
5 Participants
n=193 Participants
|
7 Participants
n=386 Participants
|
5 Participants
n=13 Participants
|
0 Participants
n=43 Participants
|
7 Participants
n=1 Participants
|
10 Participants
n=8 Participants
|
378 Participants
n=21 Participants
|
1 Participants
n=113 Participants
|
4 Participants
n=7 Participants
|
421 Participants
n=3 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
6 Participants
n=193 Participants
|
9 Participants
n=193 Participants
|
15 Participants
n=386 Participants
|
12 Participants
n=13 Participants
|
1 Participants
n=43 Participants
|
20 Participants
n=1 Participants
|
18 Participants
n=8 Participants
|
700 Participants
n=21 Participants
|
3 Participants
n=113 Participants
|
6 Participants
n=7 Participants
|
790 Participants
n=3 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=193 Participants
|
0 Participants
n=193 Participants
|
1 Participants
n=386 Participants
|
0 Participants
n=13 Participants
|
0 Participants
n=43 Participants
|
0 Participants
n=1 Participants
|
0 Participants
n=8 Participants
|
26 Participants
n=21 Participants
|
0 Participants
n=113 Participants
|
0 Participants
n=7 Participants
|
27 Participants
n=3 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=193 Participants
|
0 Participants
n=193 Participants
|
0 Participants
n=386 Participants
|
0 Participants
n=13 Participants
|
0 Participants
n=43 Participants
|
0 Participants
n=1 Participants
|
0 Participants
n=8 Participants
|
2 Participants
n=21 Participants
|
0 Participants
n=113 Participants
|
0 Participants
n=7 Participants
|
2 Participants
n=3 Participants
|
|
Race (NIH/OMB)
Asian
|
1 Participants
n=193 Participants
|
0 Participants
n=193 Participants
|
1 Participants
n=386 Participants
|
1 Participants
n=13 Participants
|
0 Participants
n=43 Participants
|
2 Participants
n=1 Participants
|
3 Participants
n=8 Participants
|
198 Participants
n=21 Participants
|
0 Participants
n=113 Participants
|
1 Participants
n=7 Participants
|
207 Participants
n=3 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=193 Participants
|
0 Participants
n=193 Participants
|
0 Participants
n=386 Participants
|
0 Participants
n=13 Participants
|
0 Participants
n=43 Participants
|
0 Participants
n=1 Participants
|
0 Participants
n=8 Participants
|
2 Participants
n=21 Participants
|
0 Participants
n=113 Participants
|
0 Participants
n=7 Participants
|
2 Participants
n=3 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=193 Participants
|
0 Participants
n=193 Participants
|
2 Participants
n=386 Participants
|
1 Participants
n=13 Participants
|
0 Participants
n=43 Participants
|
0 Participants
n=1 Participants
|
0 Participants
n=8 Participants
|
24 Participants
n=21 Participants
|
0 Participants
n=113 Participants
|
0 Participants
n=7 Participants
|
27 Participants
n=3 Participants
|
|
Race (NIH/OMB)
White
|
5 Participants
n=193 Participants
|
10 Participants
n=193 Participants
|
13 Participants
n=386 Participants
|
10 Participants
n=13 Participants
|
1 Participants
n=43 Participants
|
16 Participants
n=1 Participants
|
15 Participants
n=8 Participants
|
502 Participants
n=21 Participants
|
3 Participants
n=113 Participants
|
5 Participants
n=7 Participants
|
580 Participants
n=3 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=193 Participants
|
0 Participants
n=193 Participants
|
0 Participants
n=386 Participants
|
0 Participants
n=13 Participants
|
0 Participants
n=43 Participants
|
0 Participants
n=1 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=113 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=3 Participants
|
PRIMARY outcome
Timeframe: Cycle 1 (cycle length = 28 days)Population: All Participants who received at least 1 or more doses of selpercatinib and had evaluable data for this outcome.
The MTD is defined as the highest dose level at which none of the first 3 treated patients, or not more than 1 of the first 6 treated patients, experiences a DLT. A DLT is any adverse events that starts on or after first administration of study drug, as defined by National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0. * Any Grade(G) ≥3 nonhematologic toxicity, excluding * G3 AST, ALT, and/or total bilirubin elevation for \<7 days. * G3 neutropenia \<7 days * G3 thrombocytopenia without clinically significant bleeding * G3 or G4 lymphopenia. * First occurrence of G3 or G4 electrolyte abnormalities * G3 fatigue, weakness, nausea; other manageable constitutional symptom * G3 or G4 vomiting or diarrhea that lasts for \<48hours with antiemetic/antidiarrheal medication in case of G3 and \<24 hours in case of G4 * G4 manageable constitutional symptom.
Outcome measures
| Measure |
Phase 1 - Selpercatinib (All Participants)
n=827 Participants
All Phase 1 Participants who received Selpercatinib (20 mg - 240 mg) orally once daily (QD) or twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 2, Cohort 2: RET Fusion Solid Tumor Without Standard Therapy
Participants with RET Fusion solid tumor without standard first line therapy received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 2, Cohort 3: RET Mutant MTC
Participants with RET mutant medullary thyroid cancer (MTC) progressed on/intolerant to standard first line therapy received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 2, Cohort 4: RET Mutant MTC Without Standard Therapy
Participants with RET mutant MTC without prior standard first line therapy or other kinase inhibitor(s) with anti-RET activity received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 2, Cohort 5: Advanced RET Altered Solid Tumor
Participants with RET altered solid tumor (cohorts 1-4, disease not measurable; MTC not eligible for Cohort 3 or 4; MTC syndrome spectrum cancer; circulating free tumor DNA \[cfDNA+\] for RET alteration not known to be present in tumor) received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 2, Cohort 6: RET Inhibitor-Discontinued Participants
Participants otherwise eligible for Cohorts 1-5 who discontinued other RET inhibitors received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 120 mg Selpercatinib BID
Participants received Selpercatinib 120 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 160 mg Selpercatinib BID
Participants received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 200 mg Selpercatinib BID
Participants received Selpercatinib 200 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 240 mg Selpercatinib BID
Participants received Selpercatinib 240 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Phase 1: Maximum Tolerated Dose (MTD)
|
160 milligrams
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Cycle 1 (cycle length = 28 days)Population: All Participants who received at least 1 or more doses of selpercatinib and had evaluable data for this outcome.
Phase 1: RP2D
Outcome measures
| Measure |
Phase 1 - Selpercatinib (All Participants)
n=827 Participants
All Phase 1 Participants who received Selpercatinib (20 mg - 240 mg) orally once daily (QD) or twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 2, Cohort 2: RET Fusion Solid Tumor Without Standard Therapy
Participants with RET Fusion solid tumor without standard first line therapy received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 2, Cohort 3: RET Mutant MTC
Participants with RET mutant medullary thyroid cancer (MTC) progressed on/intolerant to standard first line therapy received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 2, Cohort 4: RET Mutant MTC Without Standard Therapy
Participants with RET mutant MTC without prior standard first line therapy or other kinase inhibitor(s) with anti-RET activity received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 2, Cohort 5: Advanced RET Altered Solid Tumor
Participants with RET altered solid tumor (cohorts 1-4, disease not measurable; MTC not eligible for Cohort 3 or 4; MTC syndrome spectrum cancer; circulating free tumor DNA \[cfDNA+\] for RET alteration not known to be present in tumor) received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 2, Cohort 6: RET Inhibitor-Discontinued Participants
Participants otherwise eligible for Cohorts 1-5 who discontinued other RET inhibitors received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 120 mg Selpercatinib BID
Participants received Selpercatinib 120 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 160 mg Selpercatinib BID
Participants received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 200 mg Selpercatinib BID
Participants received Selpercatinib 200 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 240 mg Selpercatinib BID
Participants received Selpercatinib 240 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Phase 1: Recommended Phase 2 Dose (RP2D)
|
160 milligrams
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Approximately for up to 7 years 8 monthsPopulation: All phase 2 participants who received at least 1 or more doses of selpercatinib and had evaluable data for this outcome.
Objective Response Rate was defined as the percentage of participants with best overall response of confirmed response (CR), or Partial response (PR). Response was confirmed by a repeat assessment no less than 28 days. * CR is defined as disappearance of all target lesions. * PR is defined as at least a 30% decrease in the sum of diameter (LD for non-nodal lesions and short axis diameter \[SAD\] for nodal lesions) of target lesions, taking as reference the baseline sum LD. ORR was assessed by independent review committee (IRC) using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. 95% confidence interval was calculated using Clopper-Pearson method.
Outcome measures
| Measure |
Phase 1 - Selpercatinib (All Participants)
n=307 Participants
All Phase 1 Participants who received Selpercatinib (20 mg - 240 mg) orally once daily (QD) or twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 2, Cohort 2: RET Fusion Solid Tumor Without Standard Therapy
n=74 Participants
Participants with RET Fusion solid tumor without standard first line therapy received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 2, Cohort 3: RET Mutant MTC
n=143 Participants
Participants with RET mutant medullary thyroid cancer (MTC) progressed on/intolerant to standard first line therapy received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 2, Cohort 4: RET Mutant MTC Without Standard Therapy
n=116 Participants
Participants with RET mutant MTC without prior standard first line therapy or other kinase inhibitor(s) with anti-RET activity received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 2, Cohort 5: Advanced RET Altered Solid Tumor
n=201 Participants
Participants with RET altered solid tumor (cohorts 1-4, disease not measurable; MTC not eligible for Cohort 3 or 4; MTC syndrome spectrum cancer; circulating free tumor DNA \[cfDNA+\] for RET alteration not known to be present in tumor) received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 2, Cohort 6: RET Inhibitor-Discontinued Participants
n=16 Participants
Participants otherwise eligible for Cohorts 1-5 who discontinued other RET inhibitors received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 120 mg Selpercatinib BID
Participants received Selpercatinib 120 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 160 mg Selpercatinib BID
Participants received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 200 mg Selpercatinib BID
Participants received Selpercatinib 200 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 240 mg Selpercatinib BID
Participants received Selpercatinib 240 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Phase 2: Objective Response Rate (ORR) Based on Independent Review Committee (IRC) Assessment
|
62.9 percentage of participants
Interval 57.2 to 68.3
|
79.7 percentage of participants
Interval 68.8 to 88.2
|
77.6 percentage of participants
Interval 69.9 to 84.2
|
82.8 percentage of participants
Interval 74.6 to 89.1
|
57.2 percentage of participants
Interval 50.1 to 64.2
|
31.3 percentage of participants
Interval 11.0 to 58.7
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Up to 28 daysPopulation: All Participants who received at least 1 or more doses of selpercatinib and had evaluable data for this outcome.
Phase 1: Number of Participants with a TRAE(s) is reported.
Outcome measures
| Measure |
Phase 1 - Selpercatinib (All Participants)
n=6 Participants
All Phase 1 Participants who received Selpercatinib (20 mg - 240 mg) orally once daily (QD) or twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 2, Cohort 2: RET Fusion Solid Tumor Without Standard Therapy
n=10 Participants
Participants with RET Fusion solid tumor without standard first line therapy received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 2, Cohort 3: RET Mutant MTC
n=16 Participants
Participants with RET mutant medullary thyroid cancer (MTC) progressed on/intolerant to standard first line therapy received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 2, Cohort 4: RET Mutant MTC Without Standard Therapy
n=12 Participants
Participants with RET mutant MTC without prior standard first line therapy or other kinase inhibitor(s) with anti-RET activity received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 2, Cohort 5: Advanced RET Altered Solid Tumor
n=1 Participants
Participants with RET altered solid tumor (cohorts 1-4, disease not measurable; MTC not eligible for Cohort 3 or 4; MTC syndrome spectrum cancer; circulating free tumor DNA \[cfDNA+\] for RET alteration not known to be present in tumor) received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 2, Cohort 6: RET Inhibitor-Discontinued Participants
n=20 Participants
Participants otherwise eligible for Cohorts 1-5 who discontinued other RET inhibitors received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 120 mg Selpercatinib BID
n=19 Participants
Participants received Selpercatinib 120 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 160 mg Selpercatinib BID
n=764 Participants
Participants received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 200 mg Selpercatinib BID
n=3 Participants
Participants received Selpercatinib 200 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 240 mg Selpercatinib BID
n=6 Participants
Participants received Selpercatinib 240 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Phase 1: Number of Participants With a Treatment-Related Adverse Event(s) (TRAE[s])
|
3 Participants
|
9 Participants
|
14 Participants
|
12 Participants
|
1 Participants
|
18 Participants
|
17 Participants
|
733 Participants
|
3 Participants
|
6 Participants
|
SECONDARY outcome
Timeframe: Up to 28 daysPopulation: All Participants who received at least 1 or more doses of selpercatinib and had evaluable data for this outcome.
Outcome measures
| Measure |
Phase 1 - Selpercatinib (All Participants)
n=6 Participants
All Phase 1 Participants who received Selpercatinib (20 mg - 240 mg) orally once daily (QD) or twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 2, Cohort 2: RET Fusion Solid Tumor Without Standard Therapy
n=10 Participants
Participants with RET Fusion solid tumor without standard first line therapy received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 2, Cohort 3: RET Mutant MTC
n=16 Participants
Participants with RET mutant medullary thyroid cancer (MTC) progressed on/intolerant to standard first line therapy received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 2, Cohort 4: RET Mutant MTC Without Standard Therapy
n=12 Participants
Participants with RET mutant MTC without prior standard first line therapy or other kinase inhibitor(s) with anti-RET activity received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 2, Cohort 5: Advanced RET Altered Solid Tumor
n=1 Participants
Participants with RET altered solid tumor (cohorts 1-4, disease not measurable; MTC not eligible for Cohort 3 or 4; MTC syndrome spectrum cancer; circulating free tumor DNA \[cfDNA+\] for RET alteration not known to be present in tumor) received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 2, Cohort 6: RET Inhibitor-Discontinued Participants
n=20 Participants
Participants otherwise eligible for Cohorts 1-5 who discontinued other RET inhibitors received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 120 mg Selpercatinib BID
n=19 Participants
Participants received Selpercatinib 120 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 160 mg Selpercatinib BID
n=764 Participants
Participants received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 200 mg Selpercatinib BID
n=3 Participants
Participants received Selpercatinib 200 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 240 mg Selpercatinib BID
n=6 Participants
Participants received Selpercatinib 240 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Phase 1: Number of Participants With an Abnormal Laboratory Values
|
6 Participants
|
10 Participants
|
14 Participants
|
12 Participants
|
1 Participants
|
20 Participants
|
19 Participants
|
764 Participants
|
3 Participants
|
6 Participants
|
SECONDARY outcome
Timeframe: Approximately for up to 9 years 8 monthsPhase 2: ORR based on RECIST 1.1 or RANO, as Appropriate to Tumor Type
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Approximately for up to 9 years 8 monthsPhase 2: ORR (by Investigator)
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Approximately for up to 9 years 8 monthsPhase 2: Best Change in Tumor Size from Baseline (by IRC and Investigator)
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Approximately for up to 9 years 8 monthsPhase 2: DOR (by IRC and Investigator)
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Approximately for up to 9 years 8 monthsPhase 2: CNS ORR (by IRC)
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Approximately for up to 9 years 8 monthsPhase 2: CNS DOR (by IRC)
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Approximately for up to 9 years 8 monthsPhase 2: Time to Any and Best Response (by IRC and Investigator)
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Approximately for up to 9 years 8 monthsPhase 2: CBR (by IRC and Investigator)
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Approximately for up to 9 years 8 monthsPhase 2: PFS (by IRC and Investigator)
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Approximately for up to 9 years 8 monthsPhase 2: OS
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Approximately for up to 9 years 8 monthsPhase 2: Percentage of Participants with any SAE(s)
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Cycle 5 Day 1 (Cycle = 28 days)Phase 2: PK: AUC of LOXO-292 (Selpercatinib)
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Cycle 5 Day 1 (Cycle = 28 days)Phase 2: PK: Cmax of LOXO-292 (Selpercatinib)
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Cycle 1 Day 8: Predose, 1, 2, 4, 8, 24 hours post dose (cycle length = 28 days)Population: All Participants who received at least 1 or more doses of selpercatinib and had PK evaluable data for this outcome.
Outcome measures
| Measure |
Phase 1 - Selpercatinib (All Participants)
n=4 Participants
All Phase 1 Participants who received Selpercatinib (20 mg - 240 mg) orally once daily (QD) or twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 2, Cohort 2: RET Fusion Solid Tumor Without Standard Therapy
n=9 Participants
Participants with RET Fusion solid tumor without standard first line therapy received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 2, Cohort 3: RET Mutant MTC
n=12 Participants
Participants with RET mutant medullary thyroid cancer (MTC) progressed on/intolerant to standard first line therapy received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 2, Cohort 4: RET Mutant MTC Without Standard Therapy
n=11 Participants
Participants with RET mutant MTC without prior standard first line therapy or other kinase inhibitor(s) with anti-RET activity received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 2, Cohort 5: Advanced RET Altered Solid Tumor
Participants with RET altered solid tumor (cohorts 1-4, disease not measurable; MTC not eligible for Cohort 3 or 4; MTC syndrome spectrum cancer; circulating free tumor DNA \[cfDNA+\] for RET alteration not known to be present in tumor) received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 2, Cohort 6: RET Inhibitor-Discontinued Participants
n=15 Participants
Participants otherwise eligible for Cohorts 1-5 who discontinued other RET inhibitors received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 120 mg Selpercatinib BID
n=10 Participants
Participants received Selpercatinib 120 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 160 mg Selpercatinib BID
n=480 Participants
Participants received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 200 mg Selpercatinib BID
n=2 Participants
Participants received Selpercatinib 200 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 240 mg Selpercatinib BID
n=3 Participants
Participants received Selpercatinib 240 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Phase 1: Pharmacokinetics (PK): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours
|
2240 nanogram*hour per milliliter (ng*h/mL)
Geometric Coefficient of Variation 36
|
4570 nanogram*hour per milliliter (ng*h/mL)
Geometric Coefficient of Variation 50
|
8450 nanogram*hour per milliliter (ng*h/mL)
Geometric Coefficient of Variation 53
|
17100 nanogram*hour per milliliter (ng*h/mL)
Geometric Coefficient of Variation 46
|
—
|
19400 nanogram*hour per milliliter (ng*h/mL)
Geometric Coefficient of Variation 49
|
42200 nanogram*hour per milliliter (ng*h/mL)
Geometric Coefficient of Variation 40
|
53700 nanogram*hour per milliliter (ng*h/mL)
Geometric Coefficient of Variation 53
|
NA nanogram*hour per milliliter (ng*h/mL)
Geometric Coefficient of Variation NA
Geometric Mean and Geometric Coefficient of Variation could not be calculated as there were only two participants. Individual values reported: 43200 ng\*h/mL; 33100 ng\*h/mL.
|
87900 nanogram*hour per milliliter (ng*h/mL)
Geometric Coefficient of Variation 20
|
SECONDARY outcome
Timeframe: Cycle 1 Day 8: Predose, 1, 2, 4, 8, 24 hours post dose (cycle length = 28 days)Population: All Participants who received at least 1 or more doses of selpercatinib and had PK evaluable data for this outcome.
Outcome measures
| Measure |
Phase 1 - Selpercatinib (All Participants)
n=4 Participants
All Phase 1 Participants who received Selpercatinib (20 mg - 240 mg) orally once daily (QD) or twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 2, Cohort 2: RET Fusion Solid Tumor Without Standard Therapy
n=9 Participants
Participants with RET Fusion solid tumor without standard first line therapy received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 2, Cohort 3: RET Mutant MTC
n=12 Participants
Participants with RET mutant medullary thyroid cancer (MTC) progressed on/intolerant to standard first line therapy received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 2, Cohort 4: RET Mutant MTC Without Standard Therapy
n=11 Participants
Participants with RET mutant MTC without prior standard first line therapy or other kinase inhibitor(s) with anti-RET activity received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 2, Cohort 5: Advanced RET Altered Solid Tumor
Participants with RET altered solid tumor (cohorts 1-4, disease not measurable; MTC not eligible for Cohort 3 or 4; MTC syndrome spectrum cancer; circulating free tumor DNA \[cfDNA+\] for RET alteration not known to be present in tumor) received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 2, Cohort 6: RET Inhibitor-Discontinued Participants
n=15 Participants
Participants otherwise eligible for Cohorts 1-5 who discontinued other RET inhibitors received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 120 mg Selpercatinib BID
n=10 Participants
Participants received Selpercatinib 120 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 160 mg Selpercatinib BID
n=486 Participants
Participants received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 200 mg Selpercatinib BID
n=2 Participants
Participants received Selpercatinib 200 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 240 mg Selpercatinib BID
n=3 Participants
Participants received Selpercatinib 240 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Phase 1: Pharmacokinetics (PK): Maximum Plasma Concentration (Cmax)
|
220 nanogram per milliliter (ng/mL)
Geometric Coefficient of Variation 14
|
275 nanogram per milliliter (ng/mL)
Geometric Coefficient of Variation 53
|
528 nanogram per milliliter (ng/mL)
Geometric Coefficient of Variation 55
|
1040 nanogram per milliliter (ng/mL)
Geometric Coefficient of Variation 46
|
—
|
1250 nanogram per milliliter (ng/mL)
Geometric Coefficient of Variation 45
|
2680 nanogram per milliliter (ng/mL)
Geometric Coefficient of Variation 27
|
3080 nanogram per milliliter (ng/mL)
Geometric Coefficient of Variation 48
|
NA nanogram per milliliter (ng/mL)
Geometric Coefficient of Variation NA
Geometric Mean and Geometric Coefficient of Variation could not be calculated as there were only two participants. Individual values reported: 3760 ng/mL;1630 ng/mL.
|
5130 nanogram per milliliter (ng/mL)
Geometric Coefficient of Variation 17
|
Adverse Events
Phase 1: 20 mg Selpercatinib QD
Serious events: 4 serious events
Other events: 6 other events
Deaths: 0 deaths
Phase 1: 20 mg Selpercatinib BID
Serious events: 8 serious events
Other events: 10 other events
Deaths: 0 deaths
Phase 1: 40 mg Selpercatinib BID
Serious events: 9 serious events
Other events: 16 other events
Deaths: 0 deaths
Phase 1: 60 mg Selpercatinib BID
Serious events: 7 serious events
Other events: 12 other events
Deaths: 0 deaths
Phase 1: 160 mg Selpercatinib QD
Serious events: 1 serious events
Other events: 1 other events
Deaths: 0 deaths
Phase 1: 80 mg Selpercatinib BID
Serious events: 13 serious events
Other events: 20 other events
Deaths: 0 deaths
Phase 1: 120 mg Selpercatinib BID
Serious events: 11 serious events
Other events: 19 other events
Deaths: 0 deaths
Phase 1: 160 mg Selpercatinib BID
Serious events: 380 serious events
Other events: 764 other events
Deaths: 0 deaths
Phase 1: 200 mg Selpercatinib BID
Serious events: 3 serious events
Other events: 3 other events
Deaths: 0 deaths
Phase 1: 240 mg Selpercatinib BID
Serious events: 3 serious events
Other events: 6 other events
Deaths: 0 deaths
Phase 2, Cohort 1: RET Fusion Solid Tumor
Serious events: 187 serious events
Other events: 307 other events
Deaths: 147 deaths
Phase 2, Cohort 2: RET Fusion Solid Tumor Without Standard Therapy
Serious events: 39 serious events
Other events: 74 other events
Deaths: 27 deaths
Phase 2, Cohort 3: RET Mutant MTC
Serious events: 93 serious events
Other events: 143 other events
Deaths: 67 deaths
Phase 2, Cohort 4: RET Mutant MTC Without Standard Therapy
Serious events: 65 serious events
Other events: 116 other events
Deaths: 18 deaths
Phase 2, Cohort 5: Advanced RET Altered Solid Tumor
Serious events: 114 serious events
Other events: 201 other events
Deaths: 83 deaths
Phase 2, Cohort 6: RET Inhibitor-Discontinued Participants
Serious events: 8 serious events
Other events: 16 other events
Deaths: 8 deaths
Serious adverse events
| Measure |
Phase 1: 20 mg Selpercatinib QD
n=6 participants at risk
Participants received Selpercatinib 20 milligrams (mg) administered orally once daily (QD), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 20 mg Selpercatinib BID
n=10 participants at risk
Participants received Selpercatinib 20 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 40 mg Selpercatinib BID
n=16 participants at risk
Participants received Selpercatinib 40 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 60 mg Selpercatinib BID
n=12 participants at risk
Participants received Selpercatinib 60 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 160 mg Selpercatinib QD
n=1 participants at risk
Participants received Selpercatinib 160 milligrams (mg) administered orally once daily (QD), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 80 mg Selpercatinib BID
n=20 participants at risk
Participants received Selpercatinib 80 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 120 mg Selpercatinib BID
n=19 participants at risk
Participants received Selpercatinib 120 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 160 mg Selpercatinib BID
n=764 participants at risk
Participants received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 200 mg Selpercatinib BID
n=3 participants at risk
Participants received Selpercatinib 200 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 240 mg Selpercatinib BID
n=6 participants at risk
Participants received Selpercatinib 240 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 2, Cohort 1: RET Fusion Solid Tumor
n=307 participants at risk
Participants with Rearranged during transfection (RET) Fusion solid tumor progressed on/intolerant to standard first line therapy received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 2, Cohort 2: RET Fusion Solid Tumor Without Standard Therapy
n=74 participants at risk
Participants with RET Fusion solid tumor without standard first line therapy received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 2, Cohort 3: RET Mutant MTC
n=143 participants at risk
Participants with RET mutant medullary thyroid cancer (MTC) progressed on/intolerant to standard first line therapy received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 2, Cohort 4: RET Mutant MTC Without Standard Therapy
n=116 participants at risk
Participants with RET mutant MTC without prior standard first line therapy or other kinase inhibitor(s) with anti-RET activity received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 2, Cohort 5: Advanced RET Altered Solid Tumor
n=201 participants at risk
Participants with RET altered solid tumor (cohorts 1-4, disease not measurable; MTC not eligible for Cohort 3 or 4; MTC syndrome spectrum cancer; circulating free tumor DNA \[cfDNA+\] for RET alteration not known to be present in tumor) received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 2, Cohort 6: RET Inhibitor-Discontinued Participants
n=16 participants at risk
Participants otherwise eligible for Cohorts 1-5 who discontinued other RET inhibitors received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Musculoskeletal and connective tissue disorders
Back pain
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.39%
3/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
2/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.00%
2/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Musculoskeletal and connective tissue disorders
Flank pain
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Musculoskeletal and connective tissue disorders
Gouty arthritis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Musculoskeletal and connective tissue disorders
Groin pain
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Musculoskeletal and connective tissue disorders
Intervertebral disc protrusion
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.39%
3/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Musculoskeletal and connective tissue disorders
Chondrocalcinosis pyrophosphate
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Musculoskeletal and connective tissue disorders
Osteolysis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Musculoskeletal and connective tissue disorders
Osteonecrosis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Musculoskeletal and connective tissue disorders
Osteonecrosis of jaw
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.39%
3/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
2/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Musculoskeletal and connective tissue disorders
Pathological fracture
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Musculoskeletal and connective tissue disorders
Rheumatoid arthritis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Musculoskeletal and connective tissue disorders
Muscle spasms
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Musculoskeletal and connective tissue disorders
Muscular weakness
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.79%
6/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.3%
4/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.00%
2/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal chest pain
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal pain
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.39%
3/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.98%
3/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Musculoskeletal and connective tissue disorders
Myopathy
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Musculoskeletal and connective tissue disorders
Neck pain
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.39%
3/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Musculoskeletal and connective tissue disorders
Spinal instability
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
B-cell lymphoma
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Basal cell carcinoma
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
5/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
2/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.7%
2/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.00%
2/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bowen's disease
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breast cancer
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cancer pain
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.79%
6/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
2/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
2/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.00%
2/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Endometrial cancer
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gastric cancer
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.00%
2/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Leukaemia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant ascites
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant melanoma
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant neoplasm progression
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant pleural effusion
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.52%
4/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.5%
3/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Meningioma
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neoplasm progression
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Blood and lymphatic system disorders
Leukopenia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Blood and lymphatic system disorders
Lymphopenia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Blood and lymphatic system disorders
Neutropenia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Blood and lymphatic system disorders
Thrombocytopenia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.79%
6/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
2/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
2/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Cardiac disorders
Accelerated idioventricular rhythm
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Cardiac disorders
Acute left ventricular failure
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Cardiac disorders
Acute myocardial infarction
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.52%
4/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.00%
2/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Cardiac disorders
Angina pectoris
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Cardiac disorders
Atrial fibrillation
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
2/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.39%
3/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
2/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.00%
2/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Cardiac disorders
Atrial flutter
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Cardiac disorders
Atrioventricular block second degree
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Cardiac disorders
Cardiac arrest
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.79%
6/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.98%
3/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.00%
2/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Cardiac disorders
Cardiac dysfunction
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Cardiac disorders
Cardiac failure
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.79%
6/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.7%
2/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-small cell lung cancer
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Cardiac disorders
Cardiac failure congestive
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreatic carcinoma
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pericardial effusion malignant
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Small cell lung cancer
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Cardiac disorders
Cardiac tamponade
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
2/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Blood and lymphatic system disorders
Anaemia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Blood and lymphatic system disorders
Disseminated intravascular coagulation
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Cardiac disorders
Cardio-respiratory arrest
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Cardiac disorders
Hypertensive heart disease
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Blood and lymphatic system disorders
Febrile neutropenia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.39%
3/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
2/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Blood and lymphatic system disorders
Leukocytosis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Eye disorders
Retinal vein occlusion
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Eye disorders
Retinal vein thrombosis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Eye disorders
Ulcerative keratitis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Eye disorders
Vision blurred
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Abdominal distension
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Abdominal hernia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Abdominal pain
|
33.3%
2/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
2/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.7%
21/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.3%
7/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.8%
4/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.4%
4/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.0%
12/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Abdominal pain upper
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
2/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Anal haemorrhage
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Cardiac disorders
Left ventricular dysfunction
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Cardiac disorders
Mitral valve incompetence
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Cardiac disorders
Myocardial infarction
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.79%
6/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.98%
3/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.6%
3/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.00%
2/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Cardiac disorders
Papillary muscle rupture
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Cardiac disorders
Pericardial effusion
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.3%
10/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.6%
5/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.8%
4/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.00%
2/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Cardiac disorders
Pericarditis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Cardiac disorders
Restrictive cardiomyopathy
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Cardiac disorders
Sinus bradycardia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Cardiac disorders
Sinus tachycardia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Cardiac disorders
Tachycardia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Cardiac disorders
Ventricular arrhythmia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Congenital, familial and genetic disorders
Intestinal malrotation
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Ear and labyrinth disorders
Hypoacusis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Ear and labyrinth disorders
Vertigo
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Endocrine disorders
Adrenal insufficiency
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.52%
4/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.7%
2/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Endocrine disorders
Hyperthyroidism
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Endocrine disorders
Hypothyroidism
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Eye disorders
Blindness unilateral
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
100.0%
1/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Eye disorders
Diplopia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Eye disorders
Retinal vascular occlusion
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Apical granuloma
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Appendix disorder
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Ascites
|
33.3%
2/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
11/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.3%
7/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.5%
5/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.7%
2/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.00%
2/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Colitis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
5/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.98%
3/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Constipation
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.79%
6/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.00%
2/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Diaphragmatic hernia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Diarrhoea
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.1%
16/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.3%
7/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.7%
2/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.8%
4/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.0%
4/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Diverticular perforation
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Diverticulum intestinal haemorrhagic
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Duodenal obstruction
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Duodenal stenosis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Eosinophilic oesophagitis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Ileus
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
2/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Gastric haemorrhage
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.52%
4/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.98%
3/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Gastric ulcer
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Gastritis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Gastrointestinal haemorrhage
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Haemorrhoids
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
2/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Duodenitis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Dysphagia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.2%
9/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.6%
8/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
2/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Enterocolitis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
50.0%
10/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.39%
3/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
2/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Enterocutaneous fistula
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Enterovesical fistula
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
General disorders
Sudden death
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Hepatobiliary disorders
Bile duct obstruction
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Incarcerated umbilical hernia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Inguinal hernia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Intestinal obstruction
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.52%
4/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Intestinal perforation
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Jejunal perforation
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Large intestinal obstruction
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Large intestine perforation
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Lower gastrointestinal haemorrhage
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Malabsorption
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Mechanical ileus
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Mesenteric artery embolism
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Nausea
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.6%
12/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.98%
3/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.7%
2/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.7%
2/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.5%
5/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Oesophageal haemorrhage
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
2/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Oesophageal obstruction
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Oesophageal stenosis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
2/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Oesophagitis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Pancreatic duct dilatation
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Pancreatitis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Pancreatitis acute
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Pneumatosis intestinalis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Retroperitoneal haematoma
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Small intestinal obstruction
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
2/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
5/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
2/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.8%
4/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Umbilical hernia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.52%
4/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Upper gastrointestinal haemorrhage
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.5%
19/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.6%
8/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.1%
3/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.1%
3/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.7%
2/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.0%
4/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
General disorders
Asthenia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
5/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.5%
3/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
General disorders
Catheter site pain
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
General disorders
Chest pain
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
General disorders
Chills
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
General disorders
Complication associated with device
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
General disorders
Disease progression
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
General disorders
Drug intolerance
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
General disorders
Fatigue
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.92%
7/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.98%
3/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.00%
2/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
General disorders
Gait disturbance
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
General disorders
General physical health deterioration
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.2%
9/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.1%
3/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.1%
3/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
General disorders
Generalised oedema
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
2/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
General disorders
Incarcerated hernia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
General disorders
Influenza like illness
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.39%
3/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.98%
3/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
General disorders
Multiple organ dysfunction syndrome
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
General disorders
Non-cardiac chest pain
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
5/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
2/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.0%
4/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
General disorders
Oedema peripheral
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
General disorders
Pain
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.52%
4/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
2/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
General disorders
Pelvic mass
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
General disorders
Performance status decreased
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
General disorders
Peripheral swelling
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
General disorders
Pyrexia
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
11/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.3%
10/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.7%
2/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
General disorders
Stenosis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Hepatobiliary disorders
Bile duct stenosis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Hepatobiliary disorders
Bile duct stone
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Hepatobiliary disorders
Biliary dilatation
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Hepatobiliary disorders
Cholangitis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.39%
3/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
2/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Hepatobiliary disorders
Cholecystitis
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.79%
6/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
1/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
2/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.7%
2/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.5%
3/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Hepatobiliary disorders
Cholecystitis acute
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.79%
6/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.98%
3/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.00%
2/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Hepatobiliary disorders
Cholelithiasis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
2/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Hepatobiliary disorders
Cholestasis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Hepatobiliary disorders
Drug-induced liver injury
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
2/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Hepatobiliary disorders
Gallbladder obstruction
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Hepatobiliary disorders
Hepatic cyst ruptured
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Hepatobiliary disorders
Hepatic failure
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Hepatobiliary disorders
Hepatic haemorrhage
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Hepatobiliary disorders
Hepatic mass
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Hepatobiliary disorders
Hepatitis acute
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Hepatobiliary disorders
Hepatobiliary disease
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Hepatobiliary disorders
Jaundice cholestatic
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Immune system disorders
Contrast media allergy
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Immune system disorders
Drug hypersensitivity
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
11/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.9%
9/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Immune system disorders
Hypersensitivity
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
5/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.0%
4/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Abdominal abscess
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Abdominal infection
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Appendicitis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Appendicitis perforated
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Bacteraemia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.39%
3/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
2/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Bacterial sepsis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Brain abscess
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Bronchitis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.39%
3/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Bursitis infective
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Campylobacter gastroenteritis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Cellulitis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.98%
3/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Cholecystitis infective
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.39%
3/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Clostridium difficile colitis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.00%
2/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Clostridium difficile infection
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.00%
2/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Corneal infection
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Corona virus infection
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.6%
12/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.0%
6/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.7%
2/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.8%
4/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.00%
2/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Device related infection
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Diverticulitis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.92%
7/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.98%
3/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.7%
2/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.00%
2/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Empyema
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Enteritis infectious
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Erysipelas
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Escherichia bacteraemia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Influenza
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.79%
6/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
2/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.00%
2/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Escherichia infection
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Escherichia pyelonephritis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Escherichia urinary tract infection
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Extradural abscess
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Eye infection viral
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Gangrene
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Gastroenteritis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.79%
6/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
2/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.5%
3/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Gastroenteritis norovirus
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Gastroenteritis salmonella
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Gastroenteritis viral
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Infection
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Infective pericardial effusion
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Sialoadenitis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Sinusitis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Staphylococcal infection
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Subcutaneous abscess
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Kidney infection
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Liver abscess
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.7%
2/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Lower respiratory tract infection
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Lung abscess
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Lung infection
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.3%
10/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.6%
5/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.1%
3/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.4%
4/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.5%
3/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Meningitis
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Meningitis bacterial
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Necrotising fasciitis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Osteomyelitis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.39%
3/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
2/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Paronychia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Parotitis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Peritonitis
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.79%
6/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
2/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.00%
2/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Peritonitis bacterial
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Pharyngitis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Pneumocystis jirovecii pneumonia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Pneumonia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.5%
42/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.9%
18/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.7%
2/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.5%
5/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.0%
7/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.0%
12/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Pneumonia bacterial
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Pneumonia pneumococcal
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Pneumonia staphylococcal
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Pyelonephritis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Respiratory tract infection
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Sepsis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
20.0%
2/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.7%
21/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.6%
8/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.3%
9/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.0%
6/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Septic shock
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.39%
3/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
2/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Tonsillitis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Upper respiratory tract infection
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.52%
4/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.7%
2/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.5%
3/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Metabolism and nutrition disorders
Tetany
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Metabolism and nutrition disorders
Tumour lysis syndrome
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.39%
3/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.39%
3/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma of head and neck
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Urinary tract infection
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.79%
6/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.98%
3/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.1%
3/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.00%
2/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Urosepsis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Viral upper respiratory tract infection
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Wound infection
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Injury, poisoning and procedural complications
Accidental overdose
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Injury, poisoning and procedural complications
Acetabulum fracture
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Injury, poisoning and procedural complications
Brain herniation
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Injury, poisoning and procedural complications
Clavicle fracture
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Injury, poisoning and procedural complications
Fall
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.79%
6/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
2/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.5%
3/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Injury, poisoning and procedural complications
Femoral neck fracture
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Injury, poisoning and procedural complications
Femur fracture
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Injury, poisoning and procedural complications
Fracture
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Injury, poisoning and procedural complications
Hip fracture
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Injury, poisoning and procedural complications
Humerus fracture
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Injury, poisoning and procedural complications
Joint dislocation
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Injury, poisoning and procedural complications
Pelvic fracture
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Injury, poisoning and procedural complications
Post procedural haemorrhage
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Injury, poisoning and procedural complications
Procedural pain
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Injury, poisoning and procedural complications
Procedural pneumothorax
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Injury, poisoning and procedural complications
Radius fracture
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Injury, poisoning and procedural complications
Rib fracture
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Injury, poisoning and procedural complications
Spinal fracture
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Injury, poisoning and procedural complications
Subarachnoid haemorrhage
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Injury, poisoning and procedural complications
Subdural haematoma
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Injury, poisoning and procedural complications
Subdural haemorrhage
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Injury, poisoning and procedural complications
Thermal burn
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Injury, poisoning and procedural complications
Tracheal haemorrhage
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Injury, poisoning and procedural complications
Traumatic haematoma
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Injury, poisoning and procedural complications
Traumatic haemothorax
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Injury, poisoning and procedural complications
Wound dehiscence
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Injury, poisoning and procedural complications
Wrist fracture
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Investigations
Alanine aminotransferase increased
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.2%
9/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
1/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.6%
5/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.0%
4/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Investigations
Aspartate aminotransferase increased
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.2%
9/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
1/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.6%
5/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.0%
4/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Investigations
Blood alkaline phosphatase increased
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
1/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Investigations
Blood bilirubin increased
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
66.7%
2/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.00%
2/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Investigations
Blood creatine phosphokinase increased
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
1/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Investigations
Blood creatinine increased
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.39%
3/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Investigations
Blood magnesium decreased
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Investigations
Ejection fraction decreased
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Investigations
Electrocardiogram qt prolonged
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Investigations
Electrocardiogram t wave inversion
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Investigations
Gamma-glutamyltransferase increased
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Investigations
Liver function test increased
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Investigations
Oxygen saturation decreased
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Investigations
Pancreatic enzymes increased
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Investigations
Procalcitonin increased
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Investigations
Staphylococcus test positive
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Investigations
Troponin i increased
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Investigations
Troponin increased
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Metabolism and nutrition disorders
Calciphylaxis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Metabolism and nutrition disorders
Decreased appetite
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.39%
3/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
2/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Metabolism and nutrition disorders
Dehydration
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.7%
13/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.3%
7/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.1%
3/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.00%
2/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Metabolism and nutrition disorders
Electrolyte imbalance
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Metabolism and nutrition disorders
Failure to thrive
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.39%
3/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
2/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Metabolism and nutrition disorders
Fluid overload
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Metabolism and nutrition disorders
Hypercalcaemia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
5/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.1%
3/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.00%
2/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Metabolism and nutrition disorders
Hyperglycaemia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Metabolism and nutrition disorders
Hyperphosphataemia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Metabolism and nutrition disorders
Hypervolaemia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Metabolism and nutrition disorders
Hypoalbuminaemia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Metabolism and nutrition disorders
Hypocalcaemia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.79%
6/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.1%
3/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.00%
2/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Metabolism and nutrition disorders
Hypoglycaemia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.52%
4/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.00%
2/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Metabolism and nutrition disorders
Hypokalaemia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.52%
4/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.5%
3/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Metabolism and nutrition disorders
Hyponatraemia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.6%
20/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
1/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.9%
9/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.1%
3/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.8%
4/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.6%
3/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.0%
6/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Metabolism and nutrition disorders
Malnutrition
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumour pain
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma of skin
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
20.0%
2/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.52%
4/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.3%
4/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.7%
2/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Thyroid neoplasm
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumour haemorrhage
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Haemorrhage intracranial
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.39%
3/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Haemorrhagic stroke
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Headache
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.92%
7/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.3%
4/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.7%
2/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Hemiparesis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.39%
3/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
2/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.00%
2/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Hydrocephalus
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Ischaemic stroke
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.39%
3/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
2/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Lethargy
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Neuralgia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Neuropathy peripheral
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Normal pressure hydrocephalus
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Partial seizures
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Peripheral motor neuropathy
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Posterior reversible encephalopathy syndrome
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Presyncope
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Sciatica
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Seizure
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.3%
10/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.3%
4/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
2/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.0%
4/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Serotonin syndrome
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Somnolence
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Spinal cord compression
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.39%
3/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Syncope
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.79%
6/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.98%
3/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.1%
3/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Toxic encephalopathy
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Transient ischaemic attack
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.79%
6/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.6%
5/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Aphasia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Brain oedema
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Cauda equina syndrome
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Cerebral haemorrhage
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.39%
3/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
2/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Cerebral infarction
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.52%
4/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Cerebrovascular accident
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.92%
7/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.98%
3/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.5%
3/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Depressed level of consciousness
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Dizziness
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.39%
3/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Embolic stroke
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Encephalopathy
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Epilepsy
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
2/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Psychiatric disorders
Suicide attempt
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Renal and urinary disorders
Acute kidney injury
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.5%
2/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.6%
12/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
1/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.6%
5/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.7%
2/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.1%
3/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.0%
4/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Renal and urinary disorders
Chronic kidney disease
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Trigeminal neuralgia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Vasogenic cerebral oedema
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Pregnancy, puerperium and perinatal conditions
Abortion spontaneous
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Product Issues
Device dislocation
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Psychiatric disorders
Confusional state
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.52%
4/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
2/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.7%
2/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
2/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Psychiatric disorders
Delirium
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.39%
3/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
2/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Psychiatric disorders
Depression
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Psychiatric disorders
Hallucination
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Psychiatric disorders
Mania
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Psychiatric disorders
Mental disorder
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.39%
3/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.5%
3/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Psychiatric disorders
Psychiatric symptom
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Renal and urinary disorders
Focal segmental glomerulosclerosis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Vascular disorders
Artery dissection
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Renal and urinary disorders
Glomerulonephropathy
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Renal and urinary disorders
Hydronephrosis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
2/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Renal and urinary disorders
Nephritis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Renal and urinary disorders
Nephrolithiasis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
2/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Vascular disorders
Deep vein thrombosis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Renal and urinary disorders
Renal cyst
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Renal and urinary disorders
Renal failure
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Renal and urinary disorders
Renal impairment
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Renal and urinary disorders
Urinary retention
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.52%
4/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.98%
3/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Renal and urinary disorders
Urinary tract obstruction
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Vascular disorders
Embolism
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.39%
3/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.98%
3/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Reproductive system and breast disorders
Adenomyosis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Vascular disorders
Hypertension
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.92%
7/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.98%
3/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.1%
3/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Reproductive system and breast disorders
Benign prostatic hyperplasia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Reproductive system and breast disorders
Oedema genital
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Reproductive system and breast disorders
Pelvic pain
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Vascular disorders
Hypotension
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.92%
7/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
2/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.5%
3/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Reproductive system and breast disorders
Uterine haemorrhage
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Acute respiratory distress syndrome
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Acute respiratory failure
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.79%
6/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
2/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.8%
4/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Aspiration
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
2/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Vascular disorders
Lymphatic fistula
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Atelectasis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Bronchial obstruction
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Choking
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Vascular disorders
Peripheral venous disease
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Chronic obstructive pulmonary disease
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.39%
3/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.7%
2/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.00%
2/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Chylothorax
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.2%
9/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.6%
5/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.5%
3/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
15.0%
3/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.1%
24/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.6%
11/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.4%
4/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.5%
5/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.7%
2/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.0%
8/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Emphysema
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Haemoptysis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Haemothorax
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Hypoxia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
5/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.3%
4/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.7%
2/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Laryngeal oedema
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Oropharyngeal pain
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.5%
27/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.2%
13/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.1%
3/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.1%
3/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
10/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Pleuritic pain
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.39%
3/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Pleurocutaneous fistula
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumonia aspiration
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.0%
8/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.6%
3/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.5%
3/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumonitis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumothorax
|
33.3%
2/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.98%
3/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.00%
2/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Productive cough
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary embolism
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.6%
12/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.6%
5/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.4%
4/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
2/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.0%
4/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary haemorrhage
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
2/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary oedema
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory failure
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.6%
12/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.0%
6/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.1%
3/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.5%
3/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Stridor
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Skin and subcutaneous tissue disorders
Drug eruption
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Skin and subcutaneous tissue disorders
Skin lesion
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Skin and subcutaneous tissue disorders
Skin ulcer
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Surgical and medical procedures
Colostomy closure
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Vascular disorders
Arterial haemorrhage
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Vascular disorders
Vascular compression
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
Other adverse events
| Measure |
Phase 1: 20 mg Selpercatinib QD
n=6 participants at risk
Participants received Selpercatinib 20 milligrams (mg) administered orally once daily (QD), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 20 mg Selpercatinib BID
n=10 participants at risk
Participants received Selpercatinib 20 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 40 mg Selpercatinib BID
n=16 participants at risk
Participants received Selpercatinib 40 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 60 mg Selpercatinib BID
n=12 participants at risk
Participants received Selpercatinib 60 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 160 mg Selpercatinib QD
n=1 participants at risk
Participants received Selpercatinib 160 milligrams (mg) administered orally once daily (QD), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 80 mg Selpercatinib BID
n=20 participants at risk
Participants received Selpercatinib 80 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 120 mg Selpercatinib BID
n=19 participants at risk
Participants received Selpercatinib 120 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 160 mg Selpercatinib BID
n=764 participants at risk
Participants received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 200 mg Selpercatinib BID
n=3 participants at risk
Participants received Selpercatinib 200 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 1: 240 mg Selpercatinib BID
n=6 participants at risk
Participants received Selpercatinib 240 milligrams (mg) administered orally twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 2, Cohort 1: RET Fusion Solid Tumor
n=307 participants at risk
Participants with Rearranged during transfection (RET) Fusion solid tumor progressed on/intolerant to standard first line therapy received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 2, Cohort 2: RET Fusion Solid Tumor Without Standard Therapy
n=74 participants at risk
Participants with RET Fusion solid tumor without standard first line therapy received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 2, Cohort 3: RET Mutant MTC
n=143 participants at risk
Participants with RET mutant medullary thyroid cancer (MTC) progressed on/intolerant to standard first line therapy received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 2, Cohort 4: RET Mutant MTC Without Standard Therapy
n=116 participants at risk
Participants with RET mutant MTC without prior standard first line therapy or other kinase inhibitor(s) with anti-RET activity received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 2, Cohort 5: Advanced RET Altered Solid Tumor
n=201 participants at risk
Participants with RET altered solid tumor (cohorts 1-4, disease not measurable; MTC not eligible for Cohort 3 or 4; MTC syndrome spectrum cancer; circulating free tumor DNA \[cfDNA+\] for RET alteration not known to be present in tumor) received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
Phase 2, Cohort 6: RET Inhibitor-Discontinued Participants
n=16 participants at risk
Participants otherwise eligible for Cohorts 1-5 who discontinued other RET inhibitors received Selpercatinib 160 milligrams (mg) administered orally twice daily (BID), in a continuous 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Cardiac disorders
Myocardial infarction
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.79%
6/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.98%
3/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.6%
3/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.00%
2/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Cardiac disorders
Palpitations
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.4%
26/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
2/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.3%
7/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.1%
6/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.1%
3/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.0%
7/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.5%
7/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Cardiac disorders
Pericardial effusion
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.5%
27/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.9%
12/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.1%
3/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.9%
7/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.6%
3/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.0%
4/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Cardiac disorders
Pulmonary valve incompetence
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Cardiac disorders
Sinus bradycardia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.5%
27/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
1/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.3%
10/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.7%
2/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.5%
5/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.3%
5/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.5%
7/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Cardiac disorders
Sinus tachycardia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
20.0%
4/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.1%
16/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.3%
7/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.1%
3/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.1%
3/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.3%
5/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.5%
3/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Ear and labyrinth disorders
Eustachian tube obstruction
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Vomiting
|
33.3%
2/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
60.0%
6/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
31.2%
5/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
2/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
100.0%
1/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
30.0%
6/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
21.1%
4/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
28.0%
214/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
66.7%
2/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
2/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
26.7%
82/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
28.4%
21/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
32.9%
47/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
29.3%
34/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
28.4%
57/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
18.8%
3/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Ear and labyrinth disorders
Hypoacusis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.3%
10/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.3%
7/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.7%
2/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.7%
2/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Ear and labyrinth disorders
Tinnitus
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.8%
37/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.6%
11/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
9.5%
7/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.2%
6/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
7.8%
9/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.5%
5/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Ear and labyrinth disorders
Vertigo
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.9%
30/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.9%
9/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.1%
3/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.1%
3/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.0%
7/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
10/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Endocrine disorders
Hyperthyroidism
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.0%
23/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.3%
10/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.7%
2/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.9%
7/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.6%
3/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.5%
3/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Endocrine disorders
Hypothyroidism
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
18.8%
3/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
25.0%
3/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
20.0%
4/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
11.0%
84/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.7%
33/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
9.5%
7/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
9.1%
13/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
17.2%
20/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.9%
22/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Eye disorders
Blindness unilateral
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
100.0%
1/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Eye disorders
Conjunctivitis allergic
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Eye disorders
Dry eye
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
20.0%
2/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
7.6%
58/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.8%
21/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.1%
6/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
7.7%
11/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.3%
12/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
7.0%
14/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Eye disorders
Periorbital oedema
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
20.0%
2/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
100.0%
1/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.5%
2/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
7.6%
58/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.8%
21/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.4%
4/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
7.7%
11/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.3%
12/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.0%
16/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Eye disorders
Vision blurred
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
30.0%
3/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
7.5%
57/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
19/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.8%
5/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.5%
15/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
9.5%
11/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.5%
13/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Abdominal distension
|
50.0%
3/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
2/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
100.0%
1/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
25.0%
5/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
26.3%
5/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
14.4%
110/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
2/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
11.7%
36/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.1%
6/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
19.6%
28/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
24.1%
28/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
14.9%
30/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
General disorders
Asthenia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
18.8%
3/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.2%
93/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.5%
26/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
14.9%
11/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
14.7%
21/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.9%
15/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.4%
21/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
31.2%
5/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Abdominal pain
|
66.7%
4/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
40.0%
4/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
37.5%
6/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
35.0%
7/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
26.3%
5/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
28.7%
219/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
66.7%
2/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
2/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
23.1%
71/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.8%
25/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
37.8%
54/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
29.3%
34/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
32.3%
65/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Abdominal pain upper
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
20.0%
2/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.5%
2/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
11.0%
84/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
11.1%
34/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.2%
12/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.5%
15/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.6%
10/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
9.0%
18/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Ascites
|
33.3%
2/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
25.0%
3/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
100.0%
1/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
2/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
15.8%
3/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
15.8%
121/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.0%
49/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
9.5%
7/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.8%
24/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
20.7%
24/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
14.4%
29/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Colitis
|
33.3%
2/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.5%
19/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.6%
11/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.1%
3/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.6%
3/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.0%
4/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Constipation
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
50.0%
5/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
31.2%
5/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
4/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
35.0%
7/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
42.1%
8/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
35.1%
268/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
1/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
2/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
29.0%
89/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
43.2%
32/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
42.0%
60/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
45.7%
53/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
31.8%
64/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
18.8%
3/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Diarrhoea
|
50.0%
3/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
50.0%
5/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
43.8%
7/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
41.7%
5/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
100.0%
1/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
45.0%
9/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
63.2%
12/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
51.6%
394/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
1/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
50.0%
3/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
55.0%
169/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
43.2%
32/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
46.9%
67/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
52.6%
61/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
50.7%
102/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
56.2%
9/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Dry mouth
|
50.0%
3/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
50.0%
5/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
37.5%
6/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
2/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
40.0%
8/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
47.4%
9/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
44.4%
339/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
50.0%
3/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
42.7%
131/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
54.1%
40/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
31.5%
45/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
56.0%
65/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
44.3%
89/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
31.2%
5/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Dyspepsia
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
20.0%
4/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
9.6%
73/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
1/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.1%
25/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.8%
5/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
13.3%
19/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
14.7%
17/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
7.5%
15/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Dysphagia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
30.0%
3/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
15.0%
3/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
15.8%
3/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
9.8%
75/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
1/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
7.5%
23/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.8%
5/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
18.2%
26/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
13.8%
16/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.5%
17/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Flatulence
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
2/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.5%
2/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.7%
51/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
1/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
2/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.9%
15/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.1%
6/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.5%
15/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
11.2%
13/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.5%
11/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Gastritis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.4%
26/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.9%
12/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.5%
5/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.4%
4/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.5%
5/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Gastrooesophageal reflux disease
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
20.0%
2/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
2/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
2/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
21.1%
4/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
15.1%
115/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
1/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.4%
38/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
23.0%
17/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
18.2%
26/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.4%
19/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
13.9%
28/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Glossitis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.79%
6/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.6%
3/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Glossodynia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.3%
10/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.3%
4/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
2/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.6%
3/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Haemorrhoids
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.1%
24/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.6%
14/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.7%
2/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.8%
4/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.6%
3/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.0%
4/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Inguinal hernia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.0%
15/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.98%
3/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.2%
6/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.3%
5/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.5%
3/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Nausea
|
66.7%
4/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
40.0%
4/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
37.5%
6/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
41.7%
5/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
65.0%
13/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
42.1%
8/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
35.1%
268/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
66.7%
2/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
2/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
31.9%
98/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
40.5%
30/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
39.2%
56/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
44.0%
51/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
35.8%
72/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
31.2%
5/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Oesophagitis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.4%
18/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.6%
5/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.4%
4/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
2/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.3%
5/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.0%
4/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Rectal haemorrhage
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.2%
9/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.3%
4/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
2/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.7%
2/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.00%
2/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Small intestinal obstruction
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
2/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.92%
7/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.98%
3/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.8%
4/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.7%
2/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Gastrointestinal disorders
Stomatitis
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
2/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
13.4%
102/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
13.7%
42/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
21.6%
16/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
9.1%
13/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.1%
14/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.4%
21/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
18.8%
3/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Vascular disorders
Hypotension
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
2/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.8%
44/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.2%
16/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.8%
5/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
7.7%
11/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.6%
3/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.5%
11/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Vascular disorders
Raynaud's phenomenon
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.2%
9/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.1%
3/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.2%
6/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Blood and lymphatic system disorders
Anaemia
|
33.3%
2/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
2/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
25.0%
5/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
26.3%
5/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
15.1%
115/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
2/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
14.7%
45/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.2%
12/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
19.6%
28/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
14.7%
17/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
14.4%
29/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Blood and lymphatic system disorders
Leukopenia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
2/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
20.0%
4/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.5%
2/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
15.8%
121/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
2/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
18.9%
58/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.2%
9/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
14.0%
20/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
14.7%
17/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
14.9%
30/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Blood and lymphatic system disorders
Lymphopenia
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
25.0%
4/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
4/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
35.0%
7/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
14.1%
108/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
1/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
11.1%
34/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
14.9%
11/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
19.6%
28/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
25.9%
30/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
11.9%
24/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Blood and lymphatic system disorders
Neutropenia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
2/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
15.8%
3/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.3%
94/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
15.3%
47/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.1%
6/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
9.1%
13/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.1%
14/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
11.4%
23/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Blood and lymphatic system disorders
Thrombocytopenia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
2/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
15.8%
3/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
18.6%
142/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
1/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
2/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
24.8%
76/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
17.6%
13/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
11.2%
16/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
15.5%
18/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
14.4%
29/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Cardiac disorders
Atrial fibrillation
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
15.0%
3/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.3%
10/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.6%
5/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.5%
5/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.6%
3/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.5%
3/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Cardiac disorders
Atrial flutter
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.39%
3/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
2/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
2/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Cardiac disorders
Cardiac failure
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.3%
10/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
2/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.1%
3/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.6%
3/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Hordeolum
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.0%
8/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
2/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
2/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.7%
2/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Influenza
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.0%
23/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.6%
5/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.7%
2/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.1%
3/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.3%
5/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
10/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Kidney infection
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Liver abscess
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.39%
3/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
1/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.7%
2/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Lung infection
|
33.3%
2/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
20.0%
2/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
2/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.2%
32/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.9%
15/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.8%
5/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.2%
6/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.9%
8/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.5%
7/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
General disorders
Catheter site pain
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.39%
3/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.3%
4/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
General disorders
Chest pain
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.9%
30/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.6%
14/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.1%
3/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.1%
3/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.2%
6/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.0%
6/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
General disorders
Chills
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
15.0%
3/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
21.1%
4/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.7%
51/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
1/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
50.0%
3/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
7.2%
22/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.8%
5/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
9.1%
13/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.6%
10/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
7.5%
15/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
General disorders
Face oedema
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
100.0%
1/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.5%
2/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
11.3%
86/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
1/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
14.7%
45/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.1%
6/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
9.8%
14/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.9%
8/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
20/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
General disorders
Fatigue
|
50.0%
3/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
60.0%
6/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
68.8%
11/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
4/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
100.0%
1/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
35.0%
7/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
52.6%
10/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
39.0%
298/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
100.0%
3/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
50.0%
3/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
36.2%
111/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
41.9%
31/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
39.2%
56/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
55.2%
64/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
39.8%
80/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
25.0%
4/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
General disorders
General physical health deterioration
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.8%
14/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
2/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.4%
4/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.5%
5/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.5%
3/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
General disorders
Generalised oedema
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.2%
17/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.9%
9/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.1%
3/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.0%
4/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
General disorders
Influenza like illness
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
20.0%
2/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
2/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.5%
2/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.8%
37/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.2%
13/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.7%
2/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.6%
8/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
9.5%
11/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.5%
11/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
General disorders
Localised oedema
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.5%
2/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.3%
25/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.3%
7/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.8%
4/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.3%
5/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
10/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
General disorders
Malaise
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.6%
35/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.5%
17/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.1%
3/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.8%
4/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.3%
5/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.0%
8/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
General disorders
Mucosal inflammation
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.1%
31/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.6%
11/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.7%
2/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.3%
9/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.4%
4/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.0%
8/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
General disorders
Non-cardiac chest pain
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
20.0%
2/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
15.0%
3/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
15.8%
3/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.5%
50/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.8%
21/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.1%
6/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
7.0%
10/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.4%
4/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
9.0%
18/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
General disorders
Oedema peripheral
|
66.7%
4/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
60.0%
6/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
25.0%
4/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
25.0%
3/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
100.0%
1/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
45.0%
9/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
42.1%
8/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
37.2%
284/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
1/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
2/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
39.4%
121/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
27.0%
20/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
44.8%
64/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
36.2%
42/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
34.3%
69/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
37.5%
6/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
General disorders
Pain
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.3%
25/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.0%
6/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.7%
2/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.9%
8/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.5%
9/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
General disorders
Performance status decreased
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
General disorders
Peripheral swelling
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.5%
34/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.3%
7/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.1%
6/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.2%
6/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
7.8%
9/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.0%
8/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
General disorders
Pyrexia
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
30.0%
3/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
20.0%
4/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
26.3%
5/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
19.6%
150/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
1/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
29.3%
90/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
18.9%
14/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
14.7%
21/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
13.8%
16/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.4%
25/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
General disorders
Xerosis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Hepatobiliary disorders
Cholecystitis
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.2%
9/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
1/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.3%
4/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
2/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.7%
2/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.5%
3/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Hepatobiliary disorders
Cholelithiasis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.92%
7/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.0%
6/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
2/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Hepatobiliary disorders
Cholestasis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.52%
4/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.7%
2/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.00%
2/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Hepatobiliary disorders
Hyperbilirubinaemia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.7%
21/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.6%
8/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.8%
4/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.7%
2/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.0%
4/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Immune system disorders
Contrast media allergy
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.6%
12/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.6%
5/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.1%
3/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.7%
2/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.5%
3/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Immune system disorders
Drug hypersensitivity
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.9%
30/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
19/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.7%
2/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
2/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.6%
3/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.5%
3/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Immune system disorders
Hypersensitivity
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.6%
20/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.6%
8/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.7%
2/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.4%
4/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.5%
7/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Immune system disorders
Seasonal allergy
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.2%
17/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
2/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.7%
2/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.8%
4/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.2%
6/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.0%
4/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Anal fungal infection
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Bronchitis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
20.0%
2/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.9%
30/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.3%
10/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
7.7%
11/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.6%
3/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.5%
7/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Cellulitis
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.1%
16/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.6%
8/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.7%
2/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.8%
4/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.4%
4/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Clostridium difficile infection
|
33.3%
2/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.39%
3/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
2/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.5%
3/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Corona virus infection
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
31.2%
5/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
2/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
21.1%
4/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
19.4%
148/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
1/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
15.3%
47/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
18.9%
14/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
19.6%
28/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
27.6%
32/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
17.9%
36/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
31.2%
5/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Cystitis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.6%
12/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.98%
3/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.8%
5/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
2/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.0%
4/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Diverticulitis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.7%
21/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.3%
7/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.7%
2/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.1%
3/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.6%
3/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.0%
8/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Gastroenteritis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.5%
19/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.9%
9/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.8%
4/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.7%
2/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.0%
6/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Gastroenteritis viral
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.7%
13/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.7%
2/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.8%
4/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.7%
2/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.0%
8/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Genital infection fungal
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Nasopharyngitis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.8%
37/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.5%
17/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.1%
3/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.2%
6/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.4%
4/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.5%
7/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Oral candidiasis
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.5%
2/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.9%
22/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.6%
11/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
2/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.4%
4/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.0%
8/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Paronychia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.6%
35/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
19/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.1%
3/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.2%
6/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.3%
5/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.0%
4/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Pharyngitis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.2%
9/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.3%
4/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
2/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.0%
4/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Pneumonia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
20.0%
2/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
18.8%
3/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
2/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
9.4%
72/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
11.4%
35/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.4%
4/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
7.0%
10/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.3%
12/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
9.5%
19/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Respiratory tract infection
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.5%
2/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.8%
14/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.0%
6/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.7%
2/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
2/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.0%
6/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Rhinitis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.0%
15/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.6%
8/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.4%
4/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Sepsis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
20.0%
2/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.1%
24/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.3%
10/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.3%
9/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.7%
2/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.0%
6/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Sialoadenitis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.52%
4/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.3%
4/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Sinusitis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
2/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.5%
50/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.2%
16/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.8%
5/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.9%
7/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
9.5%
11/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
9.0%
18/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Skin infection
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.9%
22/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.6%
8/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.4%
4/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.5%
5/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.3%
5/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.00%
2/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Staphylococcal infection
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.79%
6/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.3%
4/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.7%
2/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Subcutaneous abscess
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Injury, poisoning and procedural complications
Accidental overdose
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.39%
3/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Injury, poisoning and procedural complications
Clavicle fracture
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Tooth infection
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.7%
21/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.0%
6/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.1%
3/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
2/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.0%
7/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.5%
5/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Upper respiratory tract infection
|
33.3%
2/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
40.0%
4/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
25.0%
3/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
20.0%
4/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.5%
2/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.8%
98/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
2/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.4%
38/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.1%
6/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
13.3%
19/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
21.6%
25/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
13.4%
27/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Urinary tract infection
|
33.3%
2/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
40.0%
4/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
31.2%
5/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
25.0%
3/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
25.0%
5/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
21.1%
4/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
18.6%
142/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
50.0%
3/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
19.9%
61/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
21.6%
16/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
25.2%
36/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.4%
19/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
17.9%
36/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Urosepsis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Viral infection
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.79%
6/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.1%
3/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.00%
2/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Infections and infestations
Wound infection
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.79%
6/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
1/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.98%
3/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.1%
3/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.00%
2/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Injury, poisoning and procedural complications
Fall
|
33.3%
2/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
20.0%
2/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
31.2%
5/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
4/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
2/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
15.8%
3/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
7.7%
59/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
1/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.5%
26/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
9.5%
7/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
14.0%
20/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.3%
12/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.5%
13/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Injury, poisoning and procedural complications
Femoral neck fracture
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Injury, poisoning and procedural complications
Foot fracture
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.0%
8/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
2/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.7%
2/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.00%
2/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Injury, poisoning and procedural complications
Fracture
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
2/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Injury, poisoning and procedural complications
Hip fracture
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.52%
4/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
2/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.00%
2/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Injury, poisoning and procedural complications
Procedural pain
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.5%
19/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.3%
7/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.1%
3/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.5%
5/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.0%
6/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Injury, poisoning and procedural complications
Procedural pneumothorax
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Injury, poisoning and procedural complications
Pubis fracture
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Injury, poisoning and procedural complications
Contusion
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.2%
32/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.0%
6/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
7.0%
10/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.6%
10/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
10/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Injury, poisoning and procedural complications
Thermal burn
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.79%
6/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
2/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.0%
4/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Injury, poisoning and procedural complications
Wrist fracture
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.00%
2/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Investigations
Alanine aminotransferase increased
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
4/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
30.0%
6/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
31.6%
6/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
38.5%
294/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
66.7%
2/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
2/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
44.6%
137/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.8%
25/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
28.0%
40/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
41.4%
48/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
32.8%
66/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Investigations
Aspartate aminotransferase increased
|
50.0%
3/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
20.0%
2/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
31.2%
5/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
50.0%
6/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
40.0%
8/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
36.8%
7/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
38.7%
296/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
66.7%
2/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
2/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
44.3%
136/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
37.8%
28/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
31.5%
45/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
45.7%
53/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
67/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Investigations
Blood alkaline phosphatase increased
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
2/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
20.0%
4/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.1%
123/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
66.7%
2/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
15.6%
48/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
13.5%
10/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
18.9%
27/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.4%
19/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
13.4%
27/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Investigations
Blood bilirubin increased
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
15.0%
3/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.5%
2/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.4%
95/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
1/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
2/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
13.7%
42/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
9.5%
7/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.4%
12/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
19.8%
23/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.4%
21/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Investigations
Blood cholesterol increased
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
15.0%
3/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
7.1%
54/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.2%
13/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.7%
2/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
9.8%
14/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
14.7%
17/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.5%
13/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Injury, poisoning and procedural complications
Rib fracture
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.0%
8/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.98%
3/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.7%
2/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.0%
4/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Injury, poisoning and procedural complications
Subarachnoid haemorrhage
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Investigations
Blood lactate dehydrogenase increased
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
2/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.4%
26/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.9%
12/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.4%
4/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.6%
8/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.0%
7/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Investigations
Blood phosphorus increased
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
2/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.2%
9/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
2/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.0%
7/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Investigations
Ejection fraction decreased
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
5/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
2/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
2/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Investigations
Blood creatine phosphokinase increased
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.0%
15/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
1/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.0%
6/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.5%
5/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.6%
3/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.00%
2/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Investigations
Electrocardiogram qt prolonged
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
20.0%
4/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
15.8%
3/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
22.0%
168/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
66.7%
2/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
19.9%
61/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.2%
12/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
25.2%
36/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
22.4%
26/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
21.9%
44/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Investigations
Blood creatinine increased
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
18.8%
3/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
2/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
100.0%
1/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
25.0%
5/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
15.8%
3/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
29.5%
225/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
25.4%
78/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
20.3%
15/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
28.0%
40/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
46.6%
54/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
24.9%
50/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
25.0%
4/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Metabolism and nutrition disorders
Dehydration
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
2/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
21.1%
4/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.0%
46/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.5%
20/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.4%
4/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.5%
15/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.3%
5/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
10/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Metabolism and nutrition disorders
Electrolyte imbalance
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
1/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.00%
2/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Metabolism and nutrition disorders
Hypercalcaemia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
2/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
47/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.3%
7/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.7%
2/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.5%
15/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.3%
12/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.5%
13/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Metabolism and nutrition disorders
Hyperglycaemia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
30.0%
3/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
2/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
2/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.7%
51/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.5%
17/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.4%
4/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.5%
15/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
9.5%
11/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.5%
13/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Investigations
Gamma-glutamyltransferase increased
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.7%
21/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.6%
8/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.1%
3/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.5%
5/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.6%
3/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.5%
3/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Investigations
Liver function test increased
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.4%
18/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.0%
6/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.8%
4/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.4%
4/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.0%
4/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Investigations
Weight decreased
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
50.0%
5/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
25.0%
3/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
2/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.5%
2/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
11.4%
87/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
1/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
2/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.1%
31/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
9.5%
7/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.1%
23/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
17.2%
20/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
9.5%
19/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
18.8%
3/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Investigations
Weight increased
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
20.0%
2/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
2/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
20.0%
4/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.5%
2/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
11.5%
88/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
66.7%
2/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
7.5%
23/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.1%
6/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
19.6%
28/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.4%
19/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
11.9%
24/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Metabolism and nutrition disorders
Decreased appetite
|
33.3%
2/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
20.0%
2/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
31.2%
5/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
25.0%
3/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
100.0%
1/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
35.0%
7/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
15.8%
3/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
22.6%
173/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
2/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
26.4%
81/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
20.3%
15/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
23.1%
33/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
24.1%
28/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
18.4%
37/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
25.0%
4/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Metabolism and nutrition disorders
Hyperkalaemia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
20.0%
2/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
25.0%
3/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
100.0%
1/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
15.0%
3/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
13.2%
101/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
2/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
9.8%
30/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
13.5%
10/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
20.3%
29/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
15.5%
18/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
13.4%
27/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Metabolism and nutrition disorders
Hyperphosphataemia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
2/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
2/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.7%
82/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.5%
20/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.2%
9/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
19.6%
28/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.9%
15/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
9.0%
18/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Metabolism and nutrition disorders
Hyperuricaemia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.4%
41/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.9%
15/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.7%
2/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
7.7%
11/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.0%
7/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.0%
8/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Metabolism and nutrition disorders
Hypoalbuminaemia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
20.0%
2/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
2/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
20.0%
4/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
15.2%
116/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
1/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
50.0%
3/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
14.0%
43/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
21.6%
16/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
18.2%
26/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.9%
15/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
14.4%
29/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Metabolism and nutrition disorders
Hypocalcaemia
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
4/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
20.0%
4/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.5%
2/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
17.9%
137/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
1/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
50.0%
3/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
7.5%
23/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
18.9%
14/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
23.1%
33/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
38.8%
45/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
19.4%
39/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Metabolism and nutrition disorders
Hypoglycaemia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
15.0%
3/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.5%
42/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
2/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.9%
15/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.1%
3/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.2%
6/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.3%
5/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
9.0%
18/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Metabolism and nutrition disorders
Hypokalaemia
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
25.0%
4/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
25.0%
5/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.9%
83/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
1/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
11.4%
35/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
13.5%
10/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
9.8%
14/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.1%
14/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.4%
21/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Metabolism and nutrition disorders
Hypomagnesaemia
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
40.0%
4/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
41.7%
5/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
15.0%
3/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
26.3%
5/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
13.0%
99/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
14.0%
43/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.2%
9/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
18.2%
26/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
17.2%
20/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.4%
21/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
50.0%
5/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
37.5%
6/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
4/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
35.0%
7/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
31.6%
6/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
22.8%
174/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
17.9%
55/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
18.9%
14/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.6%
48/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
32.8%
38/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
22.4%
45/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
18.8%
3/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
20.0%
2/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
43.8%
7/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
25.0%
3/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
35.0%
7/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
36.8%
7/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
23.6%
180/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
1/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
2/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
21.8%
67/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
25.7%
19/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
23.1%
33/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
30.2%
35/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
26.9%
54/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Musculoskeletal and connective tissue disorders
Bone pain
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.9%
22/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.3%
7/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.7%
2/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.2%
6/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.6%
3/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.5%
7/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Musculoskeletal and connective tissue disorders
Flank pain
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
2/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.1%
24/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
1/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.3%
7/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.8%
5/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.9%
7/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.4%
4/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.0%
6/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Metabolism and nutrition disorders
Hyponatraemia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
100.0%
1/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
40.0%
8/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
21.1%
4/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
17.9%
137/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
66.7%
2/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
14.3%
44/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
29.7%
22/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
17.5%
25/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
21.6%
25/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
19.4%
39/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Metabolism and nutrition disorders
Hypophosphataemia
|
33.3%
2/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
2/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.5%
65/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.5%
26/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.8%
8/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.3%
9/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
9.5%
11/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
9.0%
18/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Metabolism and nutrition disorders
Tumour lysis syndrome
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.39%
3/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Metabolism and nutrition disorders
Vitamin d deficiency
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
2/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
11/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.3%
4/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.6%
8/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.5%
3/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Musculoskeletal and connective tissue disorders
Joint swelling
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
20.0%
2/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.2%
17/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.3%
7/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
2/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.9%
8/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.5%
3/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Musculoskeletal and connective tissue disorders
Muscle contracture
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Musculoskeletal and connective tissue disorders
Muscle spasms
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
20.0%
2/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
25.0%
3/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
15.0%
3/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.5%
2/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
7.9%
60/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
1/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
7.8%
24/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.8%
8/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
9.1%
13/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.3%
12/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
7.0%
14/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Musculoskeletal and connective tissue disorders
Gouty arthritis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Musculoskeletal and connective tissue disorders
Intervertebral disc protrusion
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
11/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.3%
4/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
2/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.7%
2/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.00%
2/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Agraphia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Musculoskeletal and connective tissue disorders
Muscular weakness
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
20.0%
2/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
43.8%
7/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
15.0%
3/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.5%
2/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
7.5%
57/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
1/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
2/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
9.4%
29/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.2%
9/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
11.2%
16/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.6%
10/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.5%
11/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal chest pain
|
33.3%
2/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
26.3%
5/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
7.7%
59/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
7.2%
22/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
14.9%
11/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.6%
8/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.6%
10/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.5%
17/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal pain
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
18.8%
3/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
20.0%
4/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.5%
2/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
11.6%
89/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
11.7%
36/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
13.5%
10/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
11.2%
16/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
11.2%
13/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
11.4%
23/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
20.0%
2/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
25.0%
4/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
2/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
26.3%
5/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
13.4%
102/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
14.0%
43/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
14.9%
11/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
14.0%
20/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.9%
15/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
11.9%
24/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
25.0%
4/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Musculoskeletal and connective tissue disorders
Neck pain
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
18.8%
3/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
2/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
2/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.5%
2/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
9.4%
72/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
1/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
19/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.2%
12/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
14.0%
20/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.3%
12/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.4%
21/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Aphasia
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
18.8%
3/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.2%
9/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.98%
3/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.4%
4/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
2/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.0%
4/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Musculoskeletal and connective tissue disorders
Osteonecrosis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
5/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.98%
3/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.7%
2/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
20.0%
2/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
2/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
21.1%
4/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
14.4%
110/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.7%
33/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
9.5%
7/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
14.0%
20/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
19.8%
23/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
17.9%
36/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Musculoskeletal and connective tissue disorders
Pathological fracture
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.39%
3/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
2/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Cerebral haemorrhage
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.52%
4/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.98%
3/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Musculoskeletal and connective tissue disorders
Slipping rib syndrome
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Basal cell carcinoma
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.8%
14/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.98%
3/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.8%
4/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.3%
5/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.5%
7/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Cerebrovascular accident
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
11/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.3%
4/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
2/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.5%
5/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breast cancer
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cancer pain
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.8%
14/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.3%
4/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.7%
2/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.8%
4/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.0%
6/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant melanoma
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.52%
4/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.1%
3/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant pleural effusion
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
5/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
2/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.5%
3/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Cervical radiculopathy
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma of skin
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
20.0%
2/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.2%
9/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.3%
4/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.5%
5/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.4%
4/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumour pain
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
11/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.6%
5/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.7%
2/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.5%
5/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Hypoaesthesia
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
2/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.5%
2/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
38/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.9%
12/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.4%
4/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.2%
6/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
9.5%
11/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
10/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Lethargy
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.2%
9/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
2/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
2/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.6%
3/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.00%
2/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Memory impairment
|
50.0%
3/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.3%
33/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.2%
13/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.4%
4/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.6%
8/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.9%
8/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.0%
8/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Dizziness
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
30.0%
3/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
31.2%
5/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
2/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
100.0%
1/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
25.0%
5/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
26.3%
5/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
18.3%
140/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
15.6%
48/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
24.3%
18/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
21.7%
31/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
19.0%
22/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
21.9%
44/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Dysgeusia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
20.0%
2/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
2/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.2%
78/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
2/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.7%
33/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
18.9%
14/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
7.7%
11/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
9.5%
11/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.5%
17/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Facial paresis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
2/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Headache
|
33.3%
2/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
40.0%
4/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
37.5%
6/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
41.7%
5/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
20.0%
4/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
36.8%
7/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
29.6%
226/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
1/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
26.4%
81/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
32.4%
24/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
29.4%
42/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
42.2%
49/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
27.9%
56/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
25.0%
4/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Hemiparesis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
5/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.3%
4/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.00%
2/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Hydrocephalus
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Sciatica
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.2%
17/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.6%
5/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.4%
4/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.8%
4/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.5%
5/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Seizure
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.1%
16/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.9%
9/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.7%
2/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
2/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.5%
5/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Somnolence
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
11/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.3%
7/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.0%
4/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Spinal cord compression
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.39%
3/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Neuralgia
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
11/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.98%
3/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.8%
4/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.5%
3/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Neuropathy peripheral
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.3%
48/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.9%
15/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.1%
3/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
11.2%
16/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.3%
5/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.0%
12/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Paraesthesia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
18.8%
3/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
15.0%
3/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
21.1%
4/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.6%
66/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
7.2%
22/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.1%
3/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
14.0%
20/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
17.2%
20/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.5%
13/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Peripheral motor neuropathy
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.92%
7/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
2/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
2/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.7%
2/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.00%
2/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Peripheral sensory neuropathy
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
20.0%
2/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.5%
2/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.9%
45/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
1/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.9%
18/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.4%
4/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.6%
8/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
7.8%
9/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
7.5%
15/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Presyncope
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.6%
12/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.6%
5/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
2/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.7%
2/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.5%
3/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Psychiatric disorders
Hallucination
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.26%
2/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Psychiatric disorders
Insomnia
|
33.3%
2/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
30.0%
3/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
15.0%
3/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
15.8%
3/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
17.0%
130/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
1/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.9%
52/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
17.6%
13/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
19.6%
28/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
19.0%
22/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
14.9%
30/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Psychiatric disorders
Libido decreased
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.0%
15/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
2/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.5%
5/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.2%
6/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.5%
3/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Psychiatric disorders
Mental disorder
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
5/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.5%
5/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Syncope
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.1%
16/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.3%
7/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.5%
5/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.7%
2/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.5%
5/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Transient ischaemic attack
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.92%
7/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.6%
5/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.00%
2/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Nervous system disorders
Tremor
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.3%
33/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.3%
10/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.7%
2/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.6%
8/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.6%
3/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.5%
13/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Psychiatric disorders
Anxiety
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
25.0%
4/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.2%
63/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
1/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
2/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
7.5%
23/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.4%
4/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
14.7%
21/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.3%
12/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.0%
12/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Psychiatric disorders
Confusional state
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
18.8%
3/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
100.0%
1/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.5%
2/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.0%
23/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.9%
9/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.8%
5/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.6%
8/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.6%
3/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.0%
6/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Psychiatric disorders
Delirium
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
2/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.6%
12/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.0%
6/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.1%
3/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.7%
2/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.0%
4/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Psychiatric disorders
Depression
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
2/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.5%
2/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.4%
49/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
2/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.9%
12/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.4%
4/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
9.1%
13/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.1%
14/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
7.5%
15/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Renal and urinary disorders
Micturition urgency
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.5%
19/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.0%
6/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.7%
2/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.5%
5/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.0%
7/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.5%
3/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Renal and urinary disorders
Nephrolithiasis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.2%
9/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.98%
3/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.7%
2/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
2/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.7%
2/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Renal and urinary disorders
Pollakiuria
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
2/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.6%
43/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.2%
13/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
9.5%
7/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
9.1%
13/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.0%
7/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
10/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Renal and urinary disorders
Proteinuria
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
25.0%
3/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
2/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.1%
62/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
1/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
2/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.5%
26/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.8%
5/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
9.8%
14/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
9.5%
11/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
7.0%
14/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Renal and urinary disorders
Renal failure
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.0%
15/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.98%
3/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.1%
3/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.1%
3/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.0%
7/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Renal and urinary disorders
Urinary retention
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.2%
32/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.2%
13/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.1%
3/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.3%
9/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.4%
4/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.0%
8/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Reproductive system and breast disorders
Benign prostatic hyperplasia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.79%
6/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.7%
2/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
2/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.5%
3/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Renal and urinary disorders
Acute kidney injury
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
2/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
2/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
15.8%
3/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.6%
43/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
1/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.2%
13/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.4%
4/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
11.2%
16/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.2%
6/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.0%
12/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Renal and urinary disorders
Chronic kidney disease
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.6%
20/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.6%
8/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.5%
5/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.2%
6/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Renal and urinary disorders
Dysuria
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
25.0%
4/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.4%
41/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.9%
15/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.4%
4/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
7.0%
10/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.6%
10/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.0%
8/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Renal and urinary disorders
Haematuria
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.3%
33/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.6%
8/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.7%
2/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
7.7%
11/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
7.8%
9/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.0%
8/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Reproductive system and breast disorders
Nipple pain
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.52%
4/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Acute respiratory failure
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.79%
6/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
2/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.8%
4/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Aspiration
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.79%
6/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.3%
4/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Reproductive system and breast disorders
Breast mass
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.52%
4/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
2/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Reproductive system and breast disorders
Erectile dysfunction
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
20.0%
2/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
31.2%
5/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
2/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.2%
63/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
1/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.6%
8/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.4%
4/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
14.7%
21/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
23.3%
27/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.5%
13/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Bronchial obstruction
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.50%
1/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Chronic obstructive pulmonary disease
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
5/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.7%
2/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.5%
3/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Chylothorax
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.6%
20/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.3%
10/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.1%
3/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
2/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.5%
7/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
33.3%
2/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
20.0%
2/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
25.0%
4/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
25.0%
3/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
35.0%
7/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
21.1%
4/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
23.6%
180/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
66.7%
2/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
20.5%
63/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.8%
25/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
23.8%
34/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
27.6%
32/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
24.9%
50/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Dysphonia
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
20.0%
2/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
2/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
25.0%
5/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.5%
2/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
11.3%
86/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
2/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
11.4%
35/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
18.9%
14/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
11.9%
17/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.9%
15/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.4%
21/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
50.0%
3/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
40.0%
4/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
37.5%
6/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
4/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
40.0%
8/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
26.3%
5/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
23.2%
177/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
1/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
2/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
26.1%
80/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
25.7%
19/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
23.8%
34/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
27.6%
32/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
22.4%
45/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal congestion
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
20.0%
2/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
15.0%
3/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.5%
2/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
7.1%
54/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
19/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.4%
4/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.5%
15/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.6%
10/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
7.0%
14/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Oropharyngeal pain
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
20.0%
2/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
2/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
15.0%
3/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
15.8%
3/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
9.8%
75/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
2/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.1%
31/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
20.3%
15/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.5%
15/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.2%
6/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.9%
22/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
33.3%
2/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
18.8%
3/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
15.0%
3/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
21.1%
4/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
14.8%
113/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
1/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
50.0%
3/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
15.3%
47/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
18.9%
14/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.8%
24/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.3%
12/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.4%
33/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea exertional
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
25.0%
3/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.2%
40/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.2%
13/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.4%
4/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
7.0%
10/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.9%
8/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
10/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
7.5%
57/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.5%
17/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.1%
6/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
7.0%
10/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.6%
10/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
7.5%
15/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Haemoptysis
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
20.0%
2/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.4%
18/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.6%
8/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.7%
2/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.2%
6/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.7%
2/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.5%
3/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Hypoxia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
20.0%
2/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
2/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.0%
15/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.3%
10/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.7%
2/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.8%
4/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.6%
3/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.00%
2/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Lung disorder
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
5/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
2/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Pleuritic pain
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.6%
20/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.6%
8/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.4%
4/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
2/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.6%
3/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.0%
4/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumonia aspiration
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.7%
13/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.3%
5/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.0%
4/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumonitis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.1%
16/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.3%
7/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.7%
2/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.4%
4/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.5%
3/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumothorax
|
33.3%
2/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.52%
4/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.3%
4/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.00%
2/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Productive cough
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
25.0%
4/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.5%
50/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
2/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.1%
25/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.4%
4/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
7.7%
11/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.2%
6/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.0%
12/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory failure
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.7%
13/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
1/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.3%
7/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.1%
3/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
2/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.5%
3/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Rhinorrhoea
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.4%
18/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.6%
5/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.7%
2/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.0%
7/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.5%
3/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Skin and subcutaneous tissue disorders
Alopecia
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
2/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.5%
2/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.6%
81/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
1/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
2/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.5%
26/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
17.6%
13/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.6%
8/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
17.2%
20/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.9%
22/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Skin and subcutaneous tissue disorders
Dermatitis acneiform
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.7%
28/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.2%
13/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.4%
4/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.8%
4/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.7%
2/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.5%
9/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Skin and subcutaneous tissue disorders
Dermatitis exfoliative generalised
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.52%
4/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
2/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Skin and subcutaneous tissue disorders
Drug eruption
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.52%
4/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.98%
3/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
2/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Skin and subcutaneous tissue disorders
Dry skin
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
18.8%
3/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
2/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
17.1%
131/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
1/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
2/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
17.6%
54/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
17.6%
13/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
15.4%
22/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
22.4%
26/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.9%
22/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
25.0%
4/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Skin and subcutaneous tissue disorders
Eczema
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.3%
25/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.0%
6/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.8%
5/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.1%
3/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.0%
7/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.00%
2/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Skin and subcutaneous tissue disorders
Erythema
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.9%
30/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.6%
8/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.1%
6/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.8%
4/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.6%
3/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.5%
11/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Skin and subcutaneous tissue disorders
Hyperhidrosis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
20.0%
2/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.1%
31/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.3%
7/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.1%
3/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.6%
8/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.0%
7/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.5%
9/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Skin and subcutaneous tissue disorders
Hyperkeratosis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.0%
8/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
2/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
2/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.7%
2/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.00%
2/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Skin and subcutaneous tissue disorders
Ingrowing nail
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.9%
22/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.6%
8/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.7%
2/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
2/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.2%
6/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.0%
4/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Skin and subcutaneous tissue disorders
Nail disorder
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.92%
7/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
2/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
2/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Skin and subcutaneous tissue disorders
Night sweats
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
15.8%
3/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.9%
22/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.3%
4/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
7.0%
10/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.2%
6/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.0%
6/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary embolism
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
1/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.5%
27/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.9%
12/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.4%
4/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.1%
3/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.7%
2/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.0%
8/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Skin and subcutaneous tissue disorders
Rash erythematous
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.6%
12/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.33%
1/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
2/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.7%
2/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.5%
5/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Skin and subcutaneous tissue disorders
Rash macular
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.2%
9/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
1/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.98%
3/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
2/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.0%
4/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Skin and subcutaneous tissue disorders
Rash maculo-papular
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
20.0%
2/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
25.0%
3/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
2/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
15.8%
3/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
11.1%
85/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
1/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
11.1%
34/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
17.6%
13/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
14.7%
21/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
7.8%
9/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.4%
21/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Skin and subcutaneous tissue disorders
Skin lesion
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
2/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.5%
2/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.0%
23/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.3%
7/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.7%
2/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.2%
6/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.4%
4/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.5%
9/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Skin and subcutaneous tissue disorders
Skin ulcer
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
2/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.5%
19/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.9%
9/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.9%
7/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.7%
2/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.5%
5/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Skin and subcutaneous tissue disorders
Swelling face
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.7%
36/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.3%
10/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.4%
4/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.9%
7/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.9%
8/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.0%
8/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Skin and subcutaneous tissue disorders
Toxic skin eruption
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Vascular disorders
Aneurysm
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.13%
1/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Vascular disorders
Deep vein thrombosis
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.0%
8/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.98%
3/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.7%
2/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.5%
3/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Skin and subcutaneous tissue disorders
Palmar-plantar erythrodysaesthesia syndrome
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.3%
25/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.3%
7/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.1%
3/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.2%
6/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.4%
4/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.5%
3/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Vascular disorders
Embolism
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
20.0%
2/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.4%
18/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.2%
13/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
1/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.4%
2/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
1.7%
2/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.5%
5/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Vascular disorders
Hot flush
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
20.0%
2/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
2/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.6%
35/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
3.9%
12/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
2.7%
2/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.6%
8/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.6%
10/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
4.5%
9/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Vascular disorders
Hypertension
|
33.3%
2/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
30.0%
3/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
43.8%
7/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
50.0%
6/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
50.0%
10/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
26.3%
5/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
42.7%
326/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
66.7%
2/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
35.8%
110/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
50.0%
37/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
41.3%
59/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
50.9%
59/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
43.3%
87/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
62.5%
10/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Skin and subcutaneous tissue disorders
Papule
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
5/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.65%
2/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.70%
1/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.86%
1/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
6.2%
1/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
30.0%
3/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.3%
1/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.0%
1/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
5.3%
1/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
8.9%
68/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
33.3%
2/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.1%
31/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.8%
8/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
7.0%
10/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.9%
15/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
7.5%
15/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
|
Skin and subcutaneous tissue disorders
Rash
|
0.00%
0/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
20.0%
2/10 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
12.5%
2/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
2/12 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/1 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
10.0%
2/20 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
21.1%
4/19 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
25.4%
194/764 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
0.00%
0/3 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
16.7%
1/6 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
23.8%
73/307 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
31.1%
23/74 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
21.0%
30/143 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
26.7%
31/116 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
22.9%
46/201 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
25.0%
4/16 • Phase 1: Up to 28 days; Phase 2: Up to 7 years 8 months
All Participants who received at least 1 or more doses of Selpercatinib.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place
Restriction type: GT60